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Cancer is a significant cause of morbidity in New Zealand, with breast and colorectal 
cancers being amongst the most commonly diagnosed. Therapeutic research has moved 
into immunotherapies, harnessing the immune system to target tumours. One approach 
uses virus-like particles (VLP) to activate the immune system against specific antigens 
found on tumour cells. This has been successful in normal weight murine models of 
breast and colorectal cancer. 
Obesity is a highly prevalent disease and contributes to the development of many cancers 
and may impact the efficacy of treatment. Uric acid is known to be highly immunogenic 
and chronic hyperuricemia (elevated serum urate) is likely to influence the immune 
system. 
The project aimed to test a known efficacious VLP therapy combined with anti-
programmed death ligand (PD-L)1, against models of breast and colorectal cancer in 
obese and hyperuricemic mice. Mice were grafted with either breast or colorectal cancer 
and treated with an empty vehicle, VLP alone, or VLP + anti-PD-L1. Tumours were 
either immunohistochemically stained or T-cells were stained for markers of exhaustion. 
Populations of immune cells were also determined in the blood. 
Slight increases in survival were observed in obese and hyperuricemic mice with breast 
cancer treated with VLP, although these mouse strains had reduced survival compared to 
lean mice when treated with VLP + anti-PD-L1. Obese and hyperuricemic mice had 
reduced levels of tumour-infiltrating lymphocyte (TIL) infiltrate compared to lean mice. 
TILs tended to have a greater phenotype associated with exhaustion in obese mice. 
In colorectal cancer, survival rates increased in obese mice in both treatment groups. 
Obese mice had similar levels of TIL infiltration to lean mice, which was reduced in 
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hyperuricemic mice. Treatment with VLP increased TIL frequency in obese and 
hyperuricemic mice but not in lean mice. There were no differences in TIL exhaustion in 
lean and obese mice. Obese mice had higher counts of circulating neutrophils and 
inflammatory monocytes in the blood, but had reduced lymphoid-derived dendritic cell 
and B-cell counts compared to lean mice. 
This data suggests that obese and hyperuricemic mice may have reduced responses to 
immunotherapy, however this varies based on cancer type. Reduced TIL infiltration and 
increased T-cell exhaustion seen in the breast cancer model may play a role in this.  
To examine the effect of obesity on cancer treatment in patients, data from stage I and II 
colorectal cancer patients were analysed for obesity metrics, muscle mass, and blood 
parameters to compare survival in designated subpopulations. 
Analysing data about visceral fat showed that obese females had the lowest rate of 
survival, with non-obese females and all males having similar survival levels. 
Conversely, measuring waist circumference showed that non-obese females had lower 
rates of survival than obese females, while obese males had lower rates than non-obese 
males. Patients with low muscle mass tended to have higher survival compared to those 
with normal muscle mass. Obesity resulted in higher levels of lymphocytes and albumin, 
but lower levels of neutrophils and platelets. Sarcopenic patients had decreased levels of 
lymphocytes. 
Using visceral fat as a measurement of obesity gives different survival rates compared 
with standard measures. This may be useful clinically when considering body 
composition during prognosis. Future research will investigate the effect of body 
composition on the survival of stage III and IV colorectal cancer patients and may 
facilitate the development of more personalised and effective treatment regimens.
Acknowledgements  Matthew J. Woodall 
    iv 
Acknowledgements 
Firstly, I would like to express my immense gratitude to my primary supervisor, 
Professor Sarah Young. She willingly allowed me to become part of her team, and her 
respect for all of us was a great motivator to make the most out of my project. Her 
guidance and advice, not always related to my experiments, was refreshing. I have been 
interested in the field of immunotherapy for several years now and it was exciting to be 
part of her laboratory. 
To my wonderful co-supervisors, Drs. Katrin Kramer and Silke Neumann – the most 
profound thank you is needed here. Your friendly nature and willingness to help with 
experiments and proof-reading alleviated a lot of stress I had coming into this year. I 
would especially like to mention Katrin, who was heavily involved in my project. I do 
not think that I could have done it without you. 
Dr. Sharon Pattison became an advisor for the patient side of my project. Her willingness 
to expand my project and involve me in as much as possible was unexpected but much 
appreciated. I look forward to continuing working with you next year. I would also like 
to thank Dr. Gabriel Lau, for helping me with my CT analysis. 
I felt very welcome in the Young laboratory from the moment I started, and for this, I 
thank the above people but also everyone else – Donata Maciaczyk, Estelle Peyroux, 
Hein Nguyễn, Nick Shields, Niki Zach, Peng Luo, Serena Bielli, and Yasmin Wilkinson. 
I would also like to thank Meghan Evans, who started this project for her Bachelor of 
Biomedical Science (honours). Your work has proved immensely helpful. 
Finally, to my friends, family, and the team of Anatomy demonstrators, thank you for 
your love and support. Being able to get away from the laboratory and talk with people 
doing other things meant that I could relax and then work my hardest when I was here.
Table of Contents  Matthew J. Woodall 
v 
 
Table of Contents 
ABSTRACT .............................................................................................................................................. II 
ACKNOWLEDGEMENTS ....................................................................................................................IV 
TABLE OF CONTENTS ......................................................................................................................... V 
LIST OF FIGURES............................................................................................................................... VII 
LIST OF TABLES...................................................................................................................................IX 
LIST OF ABBREVIATIONS .................................................................................................................. X 
CHAPTER 1 INTRODUCTION .............................................................................................................. 1 
1.1 AN OVERVIEW OF CANCER ............................................................................................................. 2 
1.2 THE ANTI-TUMOUR IMMUNE RESPONSE .......................................................................................... 3 
1.3 TUMOUR-INDUCED IMMUNOSUPPRESSION .................................................................................... 11 
1.4 CURRENT CANCER TREATMENTS .................................................................................................. 12 
1.5 CANCER IMMUNOTHERAPY .......................................................................................................... 13 
1.6 METABOLIC SYNDROME ............................................................................................................... 19 
1.7 THE LINK BETWEEN METABOLIC SYNDROME AND CANCER .......................................................... 22 
1.8 THE EFFECT OF METABOLIC SYNDROME ON THE IMMUNE SYSTEM ............................................... 26 
1.9 THE EFFECT OF METABOLIC SYNDROME ON IMMUNOTHERAPIES .................................................. 30 
1.10 AIMS AND RATIONALE.................................................................................................................. 31 
CHAPTER 2 MATERIALS AND METHODS .................................................................................... 34 
2.1 TUMOUR TRIALS........................................................................................................................... 35 
2.2 INVESTIGATING TUMOUR-INFILTRATING LYMPHOCYTES .............................................................. 39 
2.3 ISOLATION OF IMMUNE CELL POPULATIONS FROM THE BLOOD OF TUMOUR-BEARING MICE ......... 42 
2.4 FLOW CYTOMETRIC ANALYSIS ..................................................................................................... 42 
2.5 DESCRIPTIVE OBSERVATIONAL STUDY: THE EFFECT OF BODY COMPOSITION ON CANCER 
OUTCOMES ................................................................................................................................... 44 
2.6 STATISTICAL ANALYSIS FOR ALL DATA ........................................................................................ 49 
CHAPTER 3 RESULTS (MURINE) ..................................................................................................... 51 
3.1 TUMOUR GROWTH AND SURVIVAL RATES IN LEAN, OBESE AND HYPERURICEMIC MICE ................ 52 
3.2 ANALYSIS OF TUMOUR-INFILTRATING LYMPHOCYTES ................................................................. 65 
3.3 FREQUENCIES OF CIRCULATING IMMUNE CELLS IN LEAN AND OBESE MICE .................................. 76 
CHAPTER 4 RESULTS (HUMAN) ...................................................................................................... 81 
4.1 THE EFFECT OF BODY COMPOSITION ON 5-YEAR SURVIVAL OF COLORECTAL CANCER PATIENTS .. 82 
4.2 DIFFERENCES IN MARKERS OF INFLAMMATION IN OBESITY AND SARCOPENIA .............................. 94 
  
Table of Contents  Matthew J. Woodall 
vi 
 
CHAPTER 5 DISCUSSION ................................................................................................................... 97 
5.1 TUMOUR GROWTH AND SURVIVAL FOLLOWING IMMUNOTHERAPEUTIC TREATMENT ................... 99 
5.2 FREQUENCIES OF TILS IN BREAST AND COLORECTAL CANCER ................................................... 102 
5.3 CHARACTERISATION OF TILS IN MICE GRAFTED WITH BREAST OR COLORECTAL CANCER TUMOURS 
  ................................................................................................................................................... 104 
5.4 CHANGES TO IMMUNE POPULATIONS IN THE BLOOD FOLLOWING MC-38 TUMOUR CHALLENGE 108 
5.5 THE ROLE OF BODY COMPOSITION IN THE SURVIVAL OF PATIENTS WITH COLORECTAL CANCER . 109 
5.6 CHANGES IN IMMUNE CELLS FREQUENCIES BASED ON BODY COMPOSITION ............................... 113 
5.7 LIMITATIONS .............................................................................................................................. 115 
5.8 FUTURE DIRECTIONS .................................................................................................................. 115 
5.9 CONCLUSION .............................................................................................................................. 117 
REFERENCES ...................................................................................................................................... 119 
APPENDIX ............................................................................................................................................ 135 
SUPPLEMENTARY FIGURES .................................................................................................................. 136 
RECIPES ............................................................................................................................................... 137 
List of Tables  Matthew J. Woodall 
vii 
 
List of Figures 
Figure 1: Overview of the anti-tumour immune response .............................................. 10 
Figure 2: Simplified VLP construct ............................................................................... 16 
Figure 3: Analysis of CD3 immunohistochemical staining ........................................... 40 
Figure 4: Inclusion criteria ............................................................................................. 45 
Figure 5: Measuring body composition using CT .......................................................... 48 
Figure 6: Tumour growth and survival curves for obese mice injected with 
C57mg.MUC1 cells ........................................................................................................ 54 
Figure 7: Tumour growth and survival curves for obese mice injected with MC-38 cells
 ........................................................................................................................................ 56 
Figure 8: Tumour growth and survival curves for hyperuricemic mice injected with 
C57mg.MUC1 cells ........................................................................................................ 58 
Figure 9: Tumour growth and survival curves for hyperuricemic mice injected with MC-
38 cells ............................................................................................................................ 60 
Figure 10: Tumour growth and survival curves for lean mice injected with C57mg.MUC1 
cells ................................................................................................................................. 63 
Figure 11: Tumour growth and survival curves for lean mice injected with MC-38 cells
 ........................................................................................................................................ 64 
Figure 12: Frequency of TILs in C57mg.MUC1 and MC-38 tumours based on treatment 
group ............................................................................................................................... 67 
Figure 13: Gating strategy for phenotyping of tumour-infiltrating lymphocytes ........... 69 
Figure 14: Markers of T-cell exhaustion in C57mg.MUC1 tumours ............................. 72 
Figure 15: Markers of T-cell exhaustion in MC-38 tumours ......................................... 75 
Figure 16: Gating strategy to identify immune cell populations in the blood ................ 77 
Figure 17: Analysis of immune cell populations in the blood of tumour-bearing mice. 80 
List of Tables  Matthew J. Woodall 
viii 
 
Figure 18: 5-year survival of stage I and II colorectal cancer patients based on VFA and 
WC defined obesity ........................................................................................................ 87 
Figure 19: 5-year survival of stage I and II colorectal cancer patients stratified based on 
BMI and L3SMI ............................................................................................................. 89 
Figure 20: 5-year survival of stage I and II colorectal cancer patients based on tumour 
stage and sex ................................................................................................................... 91 
Figure 21: 5-year survival of stage I and II colorectal cancer patients based on age and 
smoking status ................................................................................................................ 93 
Figure 22: Immune cell populations in the blood of colorectal cancer patients stratified 
based on obesity ............................................................................................................. 95 
Figure 23: Immune cell populations in the blood of colorectal cancer patients stratified 
based on muscle mass ..................................................................................................... 96 
 
Supplementary Figure 1: Markers of T-cell exhaustion in spleens of C57mg.MUC1 mice
 ...................................................................................................................................... 136 
List of Tables  Matthew J. Woodall 
ix 
 
List of Tables 
Table 1: antibodies used in flow cytometry ................................................................... 43 
Table 2: Ranges for determining body composition status ............................................ 83 
Table 3: Baseline characteristics .................................................................................... 85 
 
 
List of Abbreviations  Matthew J. Woodall 
x 
 
List of Abbreviations 
AMPK 5’-AMP-activated protein kinase 
ANOVA Analysis of variance 
APC Antigen-presenting cell 
Bcl B-cell lymphoma 
BMI Body mass index 
C57BL/6 Lean mice 
CD Cluster of differentiation 
CEA Carcinoembryonic antigen 
CLS Crown-like structures 
CpG Cytosine-phosphate guanosine 
CRP C-reactive protein 
CT Computed Tomography 
CTL Cytotoxic T cell (CD8+ T-cells) 
CTLA-4 Cytotoxic T-lymphocyte-associated Protein-4 
CXCR3 CXC chemokine receptor-3 
DAB 3,3′-Diaminobenzidine 
DAMP Danger-associated molecular protein 
DC Dendritic cell  
DHEA Dehydroepiandrosterone 
DIO Diet-induced obesity 
DMEM Dulbecco’s Modified Eagle Medium 
DNA Deoxyribonucleic acid 
EDTA Ethylenediaminetetraacetic acid 
ESR Erythrocyte sedimentation rate 
FACS Fluorescence-Activated Cell Sorting 
FCS Foetal Calf Serum 
GHR Growth hormone receptor 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
H&E Haematoxylin and eosin 
HIF Hypoxia-inducible factor 
HRC CRC Health Research Council Colorectal Cancer 
HTRU Hercus Taieri Research Unit 
i.p Intraperitoneal 





IGF Insulin-like growth factor 
IGF-1R Insulin-like growth factor-1 receptor 
IL Interleukin 
IR Insulin receptor 
IRS1 Insulin receptor substrate-1 
L3/4/5 Lumbar vertebra 3/4/5 
L3SMI Skeletal muscle index at the level of the third lumbar 
vertebra 
LAG-3 Lymphocyte activation gene-3 
MHC Major Histocompatibility Complex 
MSU Monosodium urate 
mTOR Mammalian target of rapamycin 
MUC1 Mucin-1 
NF-κB  Nuclear factor kappa-light-chain-enhancer of activated B 
cells 
NHI National Health Index 
NK Natural killer cell 
NLR Neutrophil lymphocyte ratio 
NLRP  NOD-like receptor protein 
NOD Nucleotide-binding oligomerisation domain-like 
receptors 
OS Overall survival 
PD-1 Programmed death-1 
PD-L1 Programmed death ligand-1 
PI-3K Phosphatidylinositol-3 kinase 
POUND Obese mice 
PSA Prostate-specific antigen 
RBC Red blood cell 
RHDV Rabbit haemorrhagic disease virus 
RNA Ribonucleic acid 
RPMI Roswell Park Memorial Institute media 
s.c Subcutaneous 
SEM Standard error of the mean 
STAT-3 Signal transducer and activator of transcription-3 




surv.VLP-SS-MUC1 Survivin-VLP + mucin-1 
TAA Tumour-associated antigen 
TCR T-cell receptor 
TGF Tumour growth factor 
TH T helper cell (CD4+ T-cells) 
TIL Tumour-infiltrating lymphocyte 
Tim-3 T-cell immunoglobulin and mucin-domain containing-3 
TLR Toll-like receptor 
TME Tumour microenvironment 
TNF Tumour necrosis factor 
UrahPlt2/Plt2 Hyperuricemic mice 
VEGF Vascular endothelial growth factor 
VFA Visceral fat area 
VLP Virus-like particle 
VP60 Viral protein-60 
WBC White blood cell 
WC Waist circumference







Introduction  Matthew J. Woodall 
2 
 
1.1 An overview of cancer 
Cancer is a non-communicable disease brought about by changes within cells, resulting 
in their uncontrolled growth and division. Accumulated mutations of deoxyribonucleic 
acid (DNA) in these cells means that they have abnormalities in multiple regulatory 
systems, such as losing their ability to suppress cell division, becoming unresponsive to 
signals which would otherwise evoke apoptosis (programmed cell death), or over 
responding to growth factors (1). 
Cancer is one of the leading causes of mortality worldwide, and the leading cause of 
death in New Zealand (2). While frequencies in cancer type differ between geography, 
income and sex, most deaths attributed to cancer worldwide are from lung, breast, 
colorectal, stomach and liver cancers (3). Furthermore, the number of new cancer 
registrations is increasing globally (3). Low-income countries tend to be the most 
affected, with an expected increase in incidence of more than 80% by 2030. In high-
income countries, this rate is expected to increase by 40%. Low-income countries have 
the greatest burden of cancer for reasons such as reduced resource ability, fewer trained 
medical personnel, and less implemented cancer prevention strategies. Patients also tend 
to present at a later stage to a medical professional due to costs, so the disease tends to 
be more advanced and thus harder to treat (4). 
According to the latest published New Zealand Cancer Registry data (2016), breast 
cancer and colorectal cancer have significant numbers of new registrations in New 
Zealand (50.7 cases per 100,000, 41 cases per 100,000 respectively). Rates for breast 
(which almost only affects women) and colorectal cancers are higher in Māori than non-
Māori (5). 
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1.1.1 Breast cancer 
Along with lung cancer, breast cancer is the most common cancer globally (3). Invasive 
ductal carcinoma, which makes up 70-80% of breast cancer cases, is a result of the 
epithelial cells lining the lactiferous ducts of the breast proliferating. The cells eventually 
breach the basement membrane and expand into the surrounding tissue, becoming 
malignant (6). Successful public awareness campaigns in high-income countries have 
contributed to early detection and subsequent treatment of breast cancer, which has 
resulted in an estimated 5-year survival of 80%. In contrast, constraints in resources in 
low-income countries resulting in later detection when the cancer is at a more advanced 
stage means that the 5-year survival is less than 40% (7). 
1.1.2 Colorectal cancer 
Adenocarcinoma of the colon accounts for 95% of all colorectal cancers and is the result 
of an accumulation of acquired genetic and epigenetic changes (8). Together, they result 
in the formation of polyps from the normal tubular epithelium of the colon, and the polyps 
into invasive carcinoma (9). Lifestyle choices, such as cigarette smoking, obesity, 
increased red meat intake and reduced fruit and vegetable intake, have all been shown to 
be risk factors for colorectal carcinoma (10). The 5-year survival rate of localised 
colorectal cancer is at 90%, however, as the cancer becomes more widespread this drops 
significantly. 
1.2 The anti-tumour immune response 
The immune system, while best known for protecting the body from foreign invaders, is 
also capable of mounting a response against endogenous tissue. Changes in cancerous 
cells alert the immune system to recognise and respond to tumours as well. Figure 1 
shows this process in a diagrammatic form. 
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1.2.1 Tumour-associated antigens 
Tumour-associated antigens (TAAs) are abnormal proteins expressed in tumour cells 
which are the result of genetic mutations and dysregulations in genetic transcription. 
TAAs can be immunogenic and therefore be detected by the immune system, particularly 
by T-cells. TAAs vary based on the tumour and can form in different ways. Most 
commonly they can be self-antigens which are normally expressed by the specific type 
of cell, however, they are expressed in a different location or are abnormally expressed 
to the point where they become immunogenic. Other forms of TAAs are neoantigens 
which have had mutations in their structure and differ from the normal version by a few 
amino acids, antigens produced by oncogenic viruses, oncofoetal proteins such as 
carcinoembryonic antigen (CEA), or tumour-specific antigens which are expressed only 
by the tumour and are often crucial to the malignancy of the tumour itself (11). 
TAAs can be taken up and presented by antigen-presenting cells (APCs) in several ways. 
Cytoplasmic proteins can be ubiquitinated, which marks the protein for degradation in 
the proteasome, and subsequently presented on the surface of the tumour cells on Major 
Histocompatibility Complex (MHC)-I molecules (11). Another common way TAAs can 
stimulate the immune system is by being released into the extracellular environment. 
Tumour cells lose the regulation of a controlled death, so they die via a necrotic process 
(12). In this process, antigens from the tumour are released and consequently 
phagocytosed by APCs, most commonly immature dendritic cells (DCs), and presented 
on both MHC class I and II (13). 
1.2.2 Processing of TAAs by dendritic cells (DCs) 
DCs are APCs that exist in an immature state in most tissues. When tumour cells 
necrotise, danger associated molecular patterns (DAMPs), such as heat shock proteins 
and calreticulin (among others), and immunostimulatory signals are released. DAMPs 
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bind to pattern recognition receptors such as toll-like receptors (TLRs) on or within DCs 
and stimulate the DC to become activated (14). Phagocytosis of TAAs results in the 
presentation of peptide fragments on MHC-II, where extracellular peptides are presented. 
Extracellular peptides can also be displayed on MHC-I molecules through a process 
called cross-presentation. This occurs in DCs, where exogenous antigens are internalised 
first and then processed and presented on MHC-I molecules (15). Once presentation on 
MHC molecules has occurred and DCs are activated, they are able to migrate to the 
tumour-draining lymph node. There DCs interact with, and present TAAs to, T-cells via 
MHC class I and II (16).  
1.2.3 Activation of the adaptive immune system 
The activation of naïve T-cells is crucial for the induction of an anti-tumour response. 
This occurs when the antigen-MHC complex binds to the T-cell receptor (TCR), which 
recognises the particular peptide. Depending on whether this cell is a cluster of 
differentiation (CD)4+ or CD8+ origin, the CD4 or CD8 co-receptor will also bind to the 
MHC complex. Co-stimulation via CD80/86 receptors on DCs, which bind to CD28 on 
naïve T-cells, provides the second signal required for activation, differentiation and 
proliferation of T-cells into millions of clones (17). Cytokines make up a third signal, 
and determine the differentiation pathway of T-cells into different types of effector cells 
(18). 
1.2.4 T cells and the effector response 
There are two basic types of effector T-cells, CD8+ cytotoxic T lymphocytes (CTLs) and 
CD4+ T helper cells (TH cells). They differ in how they recognise and respond to antigens 
and therefore have different roles in the anti-tumour response. 
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CD4+ T-cells recognise antigens presented on MHC-II molecules. Most solid tumour 
cells lack MHC-II on their surface, resulting in activated CD4+ T cells being unable to 
directly recognise the tumour cells (19). CD4+ T-cells are the first effector cells activated 
by DCs in lymph nodes and most of their action is through helping prime CTLs. 
Numerous mouse studies have shown that this occurs through CD4+ T-cells ‘licensing’ 
lymph node-resident DCs through CD40/CD40 ligand interaction. This causes the 
upregulation of signals such as CD80/86 and the release of interferon (IFN)γ and tumour 
necrosis factor (TNF)-α, which increase the activation and differentiation of CD8+ T-
cells (20). CD4+ T-cells, particularly TH1 cells are able to help the effector CTL response 
by releasing cytokines at the tumour site. The release of IFNγ causes an upregulation of 
MHC-I molecules on tumour cells, facilitating enhanced T-cell recognition (15, 21). 
IFNγ also helps to increase the production of ligands for CXC chemokine receptor 
(CXCR)3, which is upregulated on TH1 and CD8
+ T-cells and is important in the 
migration of T-cells to the tumour site (22).  
The other type of effector cell, CD8+ T-cells, recognise antigens presented on MHC-I 
molecules which is present on all nucleated cells, including malignant cells (23). Once 
activated, CTLs leave the lymph node and scan peripheral tissue in order to find target 
cells (24). When CTLs recognise a target cell through binding of the peptide-MHC-I 
complex, there are two main methods through which they can kill the target cells. Firstly, 
binding of the Fas ligand on the surface of CTLs to the Fas receptor on the target cell 
triggers apoptosis via the classical caspase cascade. Secondly, CTLs release granules 
containing perforins and granzymes directly into the intercellular space, which induce 
apoptosis of the target cell (15). Pro-inflammatory cytokines also play a smaller role, 
mainly TNF-α and IFNγ (23). TNF-α causes amplification of the pro-inflammatory 
response, increasing the release of chemokines and cytokines, while IFNγ acts as a 
Introduction  Matthew J. Woodall 
7 
 
chemoattractant, upregulates MHC-I, increases TH1 polarisation, and may promote target 
cell death directly (25, 26). 
1.2.5 Memory T-cells 
Another important component in the anti-tumour response is the creation of memory 
CD8+ T-cells (27). During the rapid expansion of effector T-cells, a small subset of these 
cells forms a  memory CD8+ T-cell population and are capable of persistent long-term 
survival through the actions of IL-7 (upregulates the anti-apoptotic protein B-cell 
lymphoma (Bcl)-2, promoting survival) and IL-15 (a potent inducer of proliferation 
independently of antigen) (28). CD4+ T-cell help is required for the differentiation of 
CD8+ T-cells into memory T-cells, provided through the secretion of IL-2. CD4+ T-cells 
are also involved in the maintenance of the memory T-cell population, although the 
mechanism is not yet known (29). Memory T-cells are important as they reside 
throughout the body and can be rapidly reactivated when re-encountering a small amount 
of antigen, including re-expressing effector molecules (27). 
1.2.6 Immune checkpoint molecules 
In order to regulate this system, there are certain molecules which are activated and have 
either a stimulatory or inhibitory effect. Stimulatory molecules include receptors already 
discussed, such as CD28 and CD40. There are several inhibitory molecules however 
which play an important role in self-tolerance by preventing the immune system from 
becoming overactive (30). 
The stimulation of CD28 on naïve T-cells during activation by DCs also triggers the 
production of the checkpoint molecule Cytotoxic T-lymphocyte-associated Protein 
(CTLA)-4. This molecule has a greater binding affinity with CD80/86 than CD28, thus 
acts as a competitive inhibitor by blocking a key part of T-cell stimulation. Some 
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evidence suggests that this binding may even produce inhibiting signals as well, further 
counteracting CD28-CD80/86 and TCR-MHC binding (30). The relative levels of CD28 
to CTLA-4 production therefore determines whether T-cell stimulation and proliferation 
occur. 
Another inhibitory checkpoint molecule is Programmed Death (PD)-1. This is expressed 
on the surface of T-cells, B-cells and Natural Killer (NK) cells, and binds to Programmed 
Death Ligand (PD-L)-1 and 2, which is upregulated on the surface of a wide variety of 
both immune and non-immune cells, including tumour cells (30). The binding of PD-1 
to its ligand causes similar effects as CTLA-4, inhibiting T-cell proliferation, reducing 
T-cell survival, and reducing the production of key cytokines such as IFNγ and TNFα. 
The key difference between these two molecules occurs around where in the T-cell 
response cycle they have their effect. CTLA-4 functions during the priming of the 
adaptive immune system, while PD-1 has its effect during the effector response (30). 
Other inhibitory immune checkpoint molecules include lymphocyte activation gene 
(LAG)-3 (effects progression of the cell cycle) and T-cell immunoglobulin and mucin-
domain containing (Tim)-3, which inhibits the expression of cytokines such as TNF and 
IFNγ (31, 32). These are both present on the surface of T-cells. 
1.2.7 Tumour-infiltrating lymphocytes 
Tumour-infiltrating lymphocytes (TILs) are lymphocytes which have migrated into the 
tumour mass and surround or oppose the tumour cells (33). They play an important role 
within the tumour microenvironment, either targeting tumours cells through the process 
above or inducing immunosuppression as talked about in section 1.3.2 (34).  
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1.2.7.1 T-cell exhaustion 
Cancer is a chronic condition, so T-cells located within tumours have been shown to 
convert to an exhausted state due to prolonged antigen stimulation (35). This involves a 
decreased ability to cause an effector response, resulting in poorer control over cancers. 
Eventually, there is a depletion of antigen-specific T-cells (32). A hallmark of T-cell 
exhaustion is an increased expression of cell surface inhibitory receptors, including the 
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Figure 1: Overview of the anti-tumour immune response 
TAAs and DAMPs are released from dying tumour cells and phagocytosed by nearby DCs. This causes 
activation and maturation of DCs, which present antigens on both MHC-I and MHC-II. DCs then migrate 
to local lymph nodes where they activate naïve T-cells via interaction with MHC and TCR. MHC-I binds 
to the TCR-CD8 complex while MHC-II binds to the TCR-CD4 complex. CD28-CD80/86 interaction and 
the release of cytokines provide further signals for activation. Activated TH cells bind CD40 ligand to CD40 
on DCs, causing the release of IFNγ and TNFα which helps activate cytotoxic T lymphocytes. Once 
activated, the T-cells multiply and migrate to the site of the tumour where CTLs locate tumour cells by 
binding to MHC-I and initiates tumour killing via several mechanisms. TH cells increase the immune 
response by releasing IFNγ, stimulating CTLs.  
Diagram made with biorender.com. 
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1.3 Tumour-induced immunosuppression 
Ideally, the process outlined above would lead to the destruction of almost all tumours. 
However, tumour cells which can evade the immune system are selected through the 
process of tumorigenesis. 
1.3.1 Downregulated MHC expression 
One of the key ways that malignant cells are able to escape the immune system is by 
having reduced expression of the MHC-I molecule on the plasma membrane via 
epigenetic silencing (36). This results in CTLs being unable to recognise the tumour cells 
as foreign and prevents them from carrying out their effector role (37). In doing so, 
however, this makes tumour cells susceptible to killing by NK cells, which target cells 
with low levels of MHC-I. One of the main driving pressures for the selection process 
against MHC-I positive tumour cells is the interaction with CD8+ T-cells themselves, as 
they are able to successfully recognise and kill off most tumour cells in the early stages 
of tumour development (38). The remaining tumour cells, which are able to proliferate, 
tend to be from MHC-I negative predecessors, resulting in a population which has 
significant numbers of tumour cells that are deficient in this receptor (38). It is thought 
that the downregulation of MHC-I molecules reduces the efficacy of immunotherapy 
interventions (38). However, many cancers with MHC-I deficiency can be stimulated to 
express MHC-I molecules by mimicking TH1 cytokine release, such as IFNγ (38). 
However, around 30-40% of cancers with MHC-I downregulation are unable to be 
stimulated and so the use of gene therapy or T-cells that specifically recognise low MHC-
I expression may be a potential therapeutic approach (38). 
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1.3.2 Tumour microenvironment 
Various elements of the tumour microenvironment (TME) inhibits the immune system 
indirectly. The environment can be hypoxic, which inhibits TCR and CD28-mediated 
activation of lymphocytes (39). Furthermore, the poor vasculature created during 
angiogenesis, low extracellular pH and low glucose concentration found in some tumours 
are thought to affect T-cell movement, infiltration of the tumour, and function (36). 
The TME can also actively hinder immune surveillance and the immune response. 
Myeloid-derived suppressor cells, tumour associated macrophages and regulatory T-cells 
(a type of CD4+ T-cell) can be resident at the tumour site. These cells release cytokines 
such as tumour growth factor (TGF)-β and IL-10, which are immunosuppressive. They 
act by regulating lymphocyte proliferation and inhibiting the ability of DCs and 
macrophages to stimulate CD4+ T-cells respectively (40-42). Furthermore, tumour-
associated macrophages inhibit T-cell activation and also cause apoptosis of activated T-
cells. This significantly reduces the amount of lymphocytes that infiltrate the tumour 
tissue, reducing the effectiveness of the anti-tumour response. 
1.4 Current cancer treatments 
The standard treatments for cancer are surgical resection, chemotherapy and radiation 
therapy. Depending on the type of cancer, combination therapy can be effective at 
slowing the progression of disease and may be curative. However, while these therapies 
are designed to target cancer cells by targeting rapidly dividing cells, they are not specific 
for them and significant adverse side effects are common (43). 
In light of the significant side effects and in an attempt to increase the curative success 
of treatment, research has moved into new types of more targeted therapies, including 
immunotherapy. 
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1.5 Cancer immunotherapy 
Immunotherapy is an up-and-coming approach to cancer treatment. This technique aims 
to provide either passive or active immunity against cancers by stimulating the immune 
system to specifically target tumour cells. The formation of a memory response against 
these cells is then able to prevent a reoccurrence of the tumour (44). Due to its specificity, 
it may also be a way of avoiding some of the side effects of chemotherapy and radiation 
therapy (45). In the past twenty years, there have been a significant number of proof-of-
concept trials as well as clinical studies, which have shown that this is a promising 
approach. There are several types of immunotherapy being developed, including cancer 
vaccinations, adoptive cell transfer therapy, and immune checkpoint blockade (45). 
1.5.1 Cancer vaccines 
One form of immunotherapy that has shown to be promising is a cancer vaccine. It is an 
active immunotherapy that induces a specific immune response to TAAs already present 
in the patient’s body by presenting one or more antigens to APCs and triggering an 
immune response (46). Viral vectors are used in the Young laboratory, however, a brief 
description of the other forms of cancer vaccines currently under development will also 
be given. 
1.5.1.1 Viral vector vaccines 
This involves using a viral vector to deliver TAAs. The immune system has evolved to 
deal with viruses effectively, so a strong and durable response can be stimulated. A 
disadvantage, however, is that repeat vaccination is limited due to the anti-viral response 
neutralising the vector. To avoid this, different vector types can be used for repeat 
administrations. The PROSTVAC-VF/Tricom vaccine for prostate cancer involves using 
Prostate-Specific Antigen (PSA) first with a vaccinia virus, followed by booster vaccines 
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using a Fowlpox virus (47). In stage II trials the vaccine resulted in a 10 month increased 
overall survival time, however in a larger stage III trial this finding was not replicated 
(47, 48). 
Another way that viruses can be used is through virus-like particles (VLPs). This involves 
using the capsid (outer layer) proteins of a virus as a form of vehicle to insert the desired 
TAA into the body where it can then be expressed and used to activate the immune 
system. Insect, yeast or mammalian cells are used to express the VLPs as they are able 
to perform post-translational modifications, unlike bacterial cells (49). As they do not 
contain any viral genetic material, VLPs are non-replicative and non-infectious, therefore 
enhancing their safety profile. Once injected, VLPs are taken up by APCs (mainly DCs), 
broken down and the tumour antigen is displayed on MHC-I and -II, where it can activate 
CD4+ and CD8+ T-cells, as well as B-cells. TH1 responses are desired to get efficient 
activation of CTLs (49). 
The Rabbit Haemorrhagic Disease Virus (RHDV) is a virus framework for VLPs used in 
the Young laboratory. This is a non-enveloped virus from the Caliciviridae family and 
causes rabbit haemorrhagic disease in European rabbits. As it is an animal virus, it has 
been selected for therapeutic use because humans will not have any pre-existing 
immunity against the virus, which would render the vaccine invalid and is one of the 
problems with viral vaccines (50). The capsid of this virus is made up of 90 arch-like 
dimers, forming 32 cup-shaped depressions in a T=3 icosahedron which is 35-40 nm in 
diameter. By using the viral capsid proteins (180 copies of viral protein (VP)60), the 
RHDV VLP spontaneously assembles devoid of ribonucleic acid (RNA) (51). TAAs can 
then either be incorporated into the virus via genetic engineering or be conjugated onto 
the capsid itself. Studies working to optimise this technique have found that the addition 
of a processing linker between the VP60 gene and the C-terminus of the epitope to 
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prevent the epitopes from hindering VLP assembly enhances T-cell activation (52). 
Furthermore, mannosylation with a dimannoside has been shown to provide around 270 
mannose groups onto the surface of each VLP particle. This significantly increases 
uptake by providing a second route of internalisation mediated by a mannose receptor-
mediated pathway, in murine DCs, macrophages and B-cells as well as human DCs and 
macrophages (53). Dimannosylation significantly decreases tumour growth and increases 
murine survival (52). 
The RHDV VLP has been modified to contain the survivin epitope. Survivin is a member 
of the Inhibitor of Apoptosis protein family and is upregulated in a variety of cancers, 
playing an important role in inhibiting apoptosis and promoting angiogenesis (54). 
Furthermore, while present in embryological structures, it is absent in most normal 
tissues, which makes it a good target for cancer therapies (55). In this project, the 
survivin-VLP (surv.VLP) was used for models of colorectal cancer. For breast cancer 
models, the mucin-1 (MUC1) protein was conjugated onto the VLP surface via a double 
sulphide bond (surv.VLP-SS-MUC1), which corresponds to the MUC1 antigen on the 
C57mg.MUC1 cell line and is overexpressed in a variety of human cancers (56) (Figure 
2). Cytosine-phosphate guanosine (CpG) was added to the VLP solution before injection. 
It has an affinity for the VLP and conjugates to it naturally, acting as a vaccine adjuvant 
by enhancing the function of professional APCs and boosting the immune response (57, 
58). 






Figure 2: Simplified VLP construct 
The RHDV VLP is formed from 180 copies of the capsid protein VP60 and has a diameter of 35-40nm. 
The survivin epitope is recombinantly inserted into the VP60 gene and is expressed on the outer surface of 
the VLP. The MUC1 peptide is then conjugated onto the surface of the VLP as well. Before injecting, CpG 
is added to the VLP solution and naturally conjugates onto the surface as well. 
Diagram created with biorender.com 
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1.5.1.2 Autologous tumour cells 
This method involves generating a vaccine using whole tumour cells obtained from the 
patient’s tumour. These are used in combination with adjuvants, cytokines, chemokines 
or co-stimulatory molecules. This type of vaccine has the advantage of containing a wide 
spectrum of antigens and cells, maximising the amount of tumour cells that can be 
targeted and reducing the need to specify a target antigen for treatment (47). However, 
the patient’s tumour may not be accessible or a sufficient amount may not be able to be 
taken in order to prepare the vaccine. Furthermore, it can be expensive and time-
consuming to prepare these patient-specific vaccines (59). A variation of this is using 
allogeneic cells, which are derived from tumour cell lines instead of the patient’s tumour. 
An example of a vaccine produced using this technique is the GVAX vaccine. This 
vaccine is composed of killed whole tumour cells that have been genetically modified to 
secrete granulocyte-macrophage colony-stimulating factor (GM-CSF). This acts as a 
potent immunostimulatory cytokine and promotes antigen presentation, and survival and 
activation of DCs. This vaccine was successful in murine models, however, it showed 
limited efficacy in clinical trials where it has been used against prostate cancer, 
melanoma, pancreatic cancer, and lung cancer (47). 
1.5.1.3 Peptide and protein vaccines 
This involves administering peptide sequences or whole proteins from TAAs. Adjuvants 
are also used to maximise the immune response. Examples of adjuvants used in this 
context are immune checkpoint inhibitors, costimulatory molecules activators, and TLR 
ligands (45). While preclinical studies have found that peptides are able to successfully 
stimulate specific T-cell responses, significant benefit has not been found in clinical trials 
(47). A problem with this technique is that often single, short peptides are used as 
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antigens, however, these do not activate CD4+ T-cells as they can bind directly to MHC-I. 
This results in an incomplete CTL response (47). 
1.5.1.4 DC vaccination 
A greater understanding of DC biology has led to the development of this technique. 
Here, patient-derived DCs are either loaded or transfected with peptide antigen ex vivo. 
Sipuleucel-T (Provenge) was the first US Food and Drug Administration-approved 
cancer vaccine and is generated using patient-derived DCs and activating them with GM-
CSF fused to the Prostatic Acid Phosphatase antigen. It is approved for use in castration-
resistant prostate cancer. Unfortunately, the price and complexity of producing this 
vaccine have been major drawbacks for widespread use (60). 
1.5.2 Immune checkpoint blockade 
Advanced cancers can reduce the efficacy of cancer vaccines through inducing 
immunosuppression. Combination therapy with an immune checkpoint blockade has 
been shown to result in improved efficacy (61). As discussed previously, immune 
checkpoints are inhibitory signals which are important to prevent over-activation of the 
immune system resulting in an auto-immune response. It has been shown that tumours 
upregulate these molecules in order to evade immune recognition. The first immune 
checkpoint molecule targeted was CTLA-4, with two humanised antibodies being 
clinically tested in 2000. Ipilimumab was approved by the FDA in 2010 for the treatment 
of advanced melanoma. Another checkpoint inhibitor, PD-1, can be blocked enabling T-
cells specific for the cancer antigen to be activated. This will enhance the anti-tumour 
response, resulting in tumour regression (62). Therapies against both PD-1 and PD-L1, 
as well as CTLA-4 against melanoma and non-small-cell lung carcinoma, have shown 
success, and trials for these treatments against other types of cancer are underway (63). 
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Another way that some immune checkpoint monoclonal antibodies mediate tumour 
killing is by activating antibody-dependent cellular cytotoxicity (ADCC). An example of 
a drug that works in this fashion is Avelumab, which is an Immunoglobulin (Ig)G1 anti-
PD-L1 inhibitor (64). As well as blocking the interaction between the PD-1 and PD-L1, 
the IgG component of the antibody which binds to the PD-L1 receptor is able to be 
recognised by CD16 expressed on NK cells. This enables NK cells to bind to the tumour 
cells, resulting in the secretion of lytic granules. Similar to the effector function of CTLs, 
this involves the release of molecules such as perforins and granzymes, which results in 
tumour cell death (65). 
1.5.3 Adoptive cell transfer therapy 
This form of therapy involves isolating TILs from the tumour mass, expanding tumour-
specific T-cells with the desired TCR ex vivo and then reintroducing them into the body 
(66). While there have been several significant breakthroughs in this technology, patients 
must be capable of preparative immune depletion beforehand via chemotherapy or total 
body irradiation, and some groups of patients do not respond to the therapy. Furthermore, 
a major challenge is identifying tumour-specific antigens and expanding the appropriate 
T-cells so as not to cause an autoimmune response (66). 
1.6 Metabolic syndrome  
Metabolic syndrome is a cluster of disorders which often occur together and put the 
individual at an increased risk of cardiovascular disease. The main criteria include 
obesity, hyperglycaemia, hypertension and dyslipidaemia. Hyperuricemia (elevated 
levels of uric acid) is often included in this list as it is an indicator for diseases such as 
diabetes mellitus, cardiovascular disease, and chronic renal disease (67). 




Obesity is caused by an energy imbalance that favours weight gain, resulting in metabolic 
disturbances causing stress to tissues and ultimately leads to dysfunction (68). A crude 
measure for obesity is a Body Mass Index (BMI) of 30 or more, however, this is intended 
to be used as a population measure for epidemiological studies rather than on an 
individual basis (69). 
The New Zealand Health Survey (2017/2018) found that 32% of adults aged 15 and over 
are obese, which is an increase of 5% since the 2006/2007 survey. This is higher in Māori 
and Pacific adults, being 47% and 65% respectively (70). This health problem also affects 
the younger population, with 12% of children being obese, increasing to 17% of Māori 
children and 30% of Pacific children. For both adults and children, areas with greater 
rates of deprivation have higher rates of obesity (70). 
The increasing prevalence of obesity has resulted in increased morbidity and years of life 
lost due to cardiovascular disease, type-2 diabetes mellitus, osteoarthritis, psychological 
problems and obesity-related cancers (71). Reports from the World Cancer Research 
Fund and the International Agency for Research into Cancer have found that several 
types of cancer are associated with obesity, specifically endometrial, oesophageal 
adenocarcinoma, colorectal, breast cancer in postmenopausal women, prostate and renal 
cancers. Overall, the number of cases of cancer estimated to be caused by obesity is 20% 
and obesity is the second highest risk factor for cancer, after tobacco smoking (72). 
Furthermore, studies have found that obesity leads to poorer cancer treatment efficacy 
and greater mortality from cancer (72-75). 




While obesity has been strongly linked to many pathologies, muscle mass is another body 
composition factor which is important to consider. Sarcopenia is the reduction in muscle 
mass as well as the quality of muscle fibres, resulting in increased frailty as muscle 
function deteriorates (76). While it is mostly associated with ageing, sarcopenia has been 
linked to chronic diseases such as chronic obstructive pulmonary disease and cancer (77). 
1.6.3 Hyperuricemia 
Uric acid is derived in the body by the oxidation of xanthine by xanthine oxidase as part 
of the breakdown of purines (78). A systematic review published in 2015 reports the 
prevalence of hyperuricemia (generally described as uric acid levels equal to or above 
7.0 mg/dL in men or 6.0 mg/dL in women) as 8% in non-Māori and 17-19% in Māori. 
Data on the prevalence of hyperuricemia in the Pacific population is not available, 
however, in Samoa, the rate is 33% (79, 80). Diet is not considered a significant factor 
for causing hyperuricemia directly, with a purine-rich diet (specifically meat and 
seafood) only resulting in a 1-2 mg/dL increase in uric acid (79, 81). However, high waist 
circumference and increased BMI are associated with higher leptin production and 
greater rates of insulin resistance. Both of these factors have been found to reduce renal 
uric acid excretion, therefore increasing the concentration of uric acid (79). 
Hyperuricemia can lead to gout and nephrolithiasis. It is an independent risk factor for 
coronary heart disease, stroke and type-2 diabetes mellitus (80, 82). Data from multiple 
studies have found that elevated soluble uric acid levels are independently associated 
with an increased risk of all site cancer incidence (83). Furthermore, conditions 
associated with hyperuricemia such as gout, metabolic syndrome, type-2 diabetes 
mellitus, insulin resistance and obesity have all been found to result in increased risk and 
incidence of cancer in large epidemiological studies. Patients who are hyperuricemic at 
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the time of diagnosis of colorectal cancer may be more likely to lose weight and have 
liver metastases (84). 
1.7 The link between metabolic syndrome and cancer 
1.7.1 Insulin resistance 
Excess caloric intake has been shown to promote cancer cell proliferation and tumour 
progression (73). Insulin resistance is common in cases of excess adiposity. To 
compensate for this and maintain homeostatic control, insulin secretion by pancreatic β-
cells is upregulated, resulting in hyperinsulinemia. This state has been shown to increase 
the growth and aggressiveness of obesity-associated cancers (73). Insulin signalling via 
the insulin receptor is linked to the extracellular-signal-regulated kinase and 
phosphatidylinositol-3 kinase (PI-3K) pathways. Both of these pathways are involved in 
the control of motility, proliferation, and survival of cancer cells. It is conceivable that 
hyperinsulinemia activates these pathways, resulting in cancer progression. 
The PI3K pathway is also dysregulated due to an increase in neutrophils in white adipose 
tissue in obesity, promoting the proliferation of epithelial cells which can then become 
cancerous. Neutrophils produce neutrophil elastase, which cleaves insulin receptor 
substrate 1 (IRS1). This prevents it from binding to PI3K, thus causing issues in insulin-
mediated signalling downstream of the insulin receptor (IR). This leads to insulin 
resistance. Changes in this pathway are one of the most common oncogenic events 
causing cancer (85). 
Another mechanism through which hyperinsulinemia facilitates oncogenesis is the 
similarities in shape of insulin and insulin-like growth factor (IGF)-1. As a result, they 
are both able to bind to the IR and the IGF-1 receptor (IGF-1R) (86). Cell migration 
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resulting in increased tumour invasion can be induced through the activation of IGF-1R 
kinase as it causes the loss of epithelial cell integrity (87). 
Furthermore, the increase of insulin in the portal circulation due to hyperinsulinemia 
causes the upregulation of the growth hormone receptor (GHR). This results in increased 
GHR signalling, causing an increase in the synthesis of IGF-1 (88). Free IGF-1 is also 
more available as insulin decreases the hepatic expression of binding proteins of IGF-1 
(89). Increased visceral adipose tissue causes the reduction of IGF binding protein 3, 
which is the most abundant of the IGF binding proteins. This protein also has an 
independent role in preventing cancer by inducing apoptosis via tumour protein p53 and 
Bcl-2 mechanisms (88). IGF-1 causes angiogenesis and induces the synthesis of hypoxia-
inducible factor 1a (HIF-1a). Along with vascular endothelial growth factor (VEGF), this 
leads to neovascularisation and metastases. IGF-1 also inhibits p53 thus preventing 
apoptosis and inducing metastatic spread (73). IGF-2, which binds to IR and IGF-1R, is 
overexpressed in this state and leads to tumour development through similar 
mechanisms. 
1.7.2 Sex hormones 
Excess weight leads to an increase in endogenous sex hormones. Increased levels of 
circulating hormones such as dehydroepiandrosterone (DHEA), testosterone, oestrone 
and oestradiol is linked to increased risk of breast cancer in postmenopausal women (90). 
These hormones are active in tumour sites, particularly endometrial and breast tumours 
due to the hormone-dependent nature of these types of cancer. Evidence from several 
studies suggests that oestrogens are mitogenic, induce DNA damage via free radicals, 
cause genetic instability and mutations, and regulate the expression of IRS1 in breast 
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tissue (73). Furthermore, increased oestradiol concentration in the plasma causes 
endometrial proliferation, inhibits apoptosis, and promotes IGF-1 synthesis (91). 
1.7.3 Adipokines 
In an obese state, there is over-secretion of deleterious adipokines from adipose tissue 
such as IL-6, TNFα and leptin, and under-secretion of beneficial adipokines like 
adiponectin (92). High levels of leptin, which normally acts to suppress food intake, can 
promote mitosis and is pro-inflammatory, anti-apoptotic and pro-angiogenic by 
synergistically acting with VEGF (93, 94). Prostate, colon, and breast cancers have all 
been associated with an increase in leptin concentration (95). Leptin also upregulates 
oestrogen signalling and production and is therefore implicated in breast and endometrial 
cancer. (96) 
Adiponectin, which is downregulated in the obese state, has a protective role in 
carcinogenesis and is negatively correlated with cancer development (97). Low levels of 
adiponectin are associated with high levels of soluble uric acid, and high levels of uric 
acid reduce levels of adiponectin (83). This protective effect occurs by preventing insulin 
resistance, as well as activating the 5’-AMP-activated protein kinase (AMPK) pathway, 
which inhibits the mammalian target of rapamycin (mTOR). Activation of mTOR is 
associated with cell growth and proliferation and has been associated with prostate, 
ovarian, colon, breast, lung and liver cancer progression (98). Furthermore, adiponectin 
induces p53 and Bax expression and decreases Bcl-2 expression, thus stimulating 
apoptosis. It also has an anti-inflammatory role and reduces tumour spread by 
downregulating vascular adhesion molecules, angiogenesis and cell migration (99, 100). 
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1.7.4 Upregulation of the PD-1/PD-L1 pathway 
Obesity limits the anti-tumour immune response by upregulating the immune checkpoint 
molecule PD-1 (101). With elevated levels of leptin in obesity, signal transducer and 
activator of transcription (STAT)3, a major downstream transcription factor of the leptin 
receptor, is upregulated and binds to transcription sites in the promoter region of PD-1, 
increasing transcription and subsequent expression (101). It is hypothesised that this 
change is an attempt to keep inflammation in check during weight gain. However, in the 
context of a tumour, it impairs the ability of CTLs to effectively destroy cancer cells (see 
section 1.2.6), thus limiting the immune response and accelerating tumour onset and 
progression (85, 101). 
1.7.5 The effect of body composition on cancer prognosis 
When it comes to the effect of obesity on outcomes after the diagnosis of cancer, the 
literature is incomplete and conflicting. On the one hand, difficulties have been reported 
when treating obese patients. Many obese patients do not receive the appropriate dose 
intensity of chemotherapy, due to concerns about the risk of toxicity with increasing 
dosage (102). However, several analyses have shown that the risk of short-term or long-
term adverse side effects does not increase when giving an obese person the correct 
dosing compared to a lean person (103). Considering that for most agents a reduction of 
20% in dose makes tumour regrowth more likely and can cause decreased remission and 
cure rates, this is a potentially harmful practice (102). A review of radiation therapy has 
determined that obesity may have a high impact on how successful the surgery and 
subsequent radiation therapy is. This includes factors like an increased difficulty of 
performing the treatment, as well as having to increase the size of the margins due to 
possible malpositioning, which results in an increased risk of side effects (104). 
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Interestingly, patients who are classified as high-normal weight to overweight (BMI of 
23-30) at the time of stage I-III colorectal cancer diagnosis have been shown to have 
reduced all-cause mortality, with overweight patients consistently having the best 
prognosis (105). Underweight (BMI <18.5) and significantly obese (BMI >35) patients 
have the highest risks. A separate study supports this, showing a trend towards 
overweight patients having increased survival six months after cancer diagnosis 
compared to normal-weight patients with stage II colorectal cancer. In stage III and IV 
colorectal cancer, underweight patients demonstrated a significant disadvantage (106). 
However, although there have been many observations of what has been coined the 
‘obesity paradox’, one review found several errors in these studies, including different 
forms of bias, confounding, and BMI being a crude measure of obesity (107).  
When obesity was measured using Computed Tomography (CT) scans to calculate the 
cross-sectional area of fat, survival rates for non-metastatic breast cancer were decreased 
with increased adiposity and in patients with sarcopenia. Measurements using CT scans 
were also more correlated with survival than when using BMI (108). Overall, however, 
more studies need to be done to see if this effect on survival is consistent. 
1.8 The effect of metabolic syndrome on the immune system 
1.8.1 Chronic inflammation 
A significant way in which obesity can cause cancer is through its effects on the immune 
system, creating a chronic state of inflammation. With the increased intake of nutrients 
as seen in obesity and metabolic syndrome, adipose tissue is required to expand to 
accommodate the influx (68). In adults, adipocyte hypertrophy is favoured over 
hyperplasia (109). However, these hypertrophic adipocytes induce shear mechanical 
stress on the extracellular environment and activate endoplasmic reticulum and 
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mitochondrial stress responses. Overall this results in a pro-inflammatory state within 
adipose tissue (110). 
The persistent state of inflammation and stress in adipose tissue leads to apoptosis of 
adipocytes. This triggers an infiltration of inflammatory leukocytes, resulting in an 
increase in macrophage numbers within adipose tissue, which encircle the dead 
adipocytes to form crown-like structures (CLS) (85, 111). CLS have been found in 50% 
of patients with breast cancer, and are associated with higher BMI and other systemic 
markers of metabolic syndrome. The formation of CLS causes the activation of 
macrophage pattern recognition receptors, such as TLRs (85). As a result, macrophages 
are polarised towards a pro-inflammatory phenotype as opposed to an anti-inflammatory 
phenotype that macrophages in healthy adipose tissue have (112).  
Both macrophages and hypertrophic adipocytes upregulate secretion of the pro-
inflammatory mediators TNFα, IL-6, and monocyte chemoattractant protein-1 (113). 
These mediators further promote dysfunction, as well as block the production of 
adiponectin, which has anti-inflammatory effects and promotes insulin sensitivity. 
Molecules such as TNFα are also pro-angiogenic, and directly support the development 
of tumours (114). Overall, this results in the development of insulin resistance, increased 
lipolysis and impaired lipid storage (68). This change to a basal pro-inflammatory state 
has also been found to be the case in leukocytes circulating in the blood. Peripheral 
mononuclear cells display greater nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB) activation, which participates in the regulation of the inflammasome and 
upregulates pro-inflammatory genes such as those involved in cytokines and chemokines 
(115). 
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1.8.2 Lipid deposition in primary lymphoid tissue 
Mobilisation of fat stores as a result of increased lipolysis and impaired lipid storage in 
adipose tissue causes an accumulation of lipids in non-adipose tissue, including lymphoid 
tissues like bone marrow and the thymus (116). Bone marrow-derived haematopoietic 
stem cells are continuously replicating in order to maintain lymphoid (T- and B-
lymphocytes, NK cells) and myeloid-derived (monocytes, macrophages, dendritic cells, 
granulocytes, erythrocytes, megakaryocytes, mast cells) lineages of cells (117). Mature 
T-cells then travel to and undergo further development in the thymus. Both the thymus 
and bone marrow are considered to be primary lymphoid organs (118). Increased lipid 
deposits in these tissues disrupt their integrity, altering the environment in which 
leukocytes develop. In the bone marrow, this suppresses haematopoiesis and skews 
progenitor populations into producing a greater ratio of myeloid progenitor cells as 
opposed to lymphoid progenitor cells (119, 120). 
In the thymus, changes occur which resemble the natural process of thymic involution 
that normally occurs with old age (118). This includes a loss of corticomedullary 
junctions, increased perithymic adiposity, and a reduction in populations of lymphocytic 
precursor cells (120). These changes result in a reduced thymic output of naïve T-cells, 
which is likely to negatively affect immune surveillance and therefore increase the 
likelihood of immune escape of pathogens or tumours (120). 
1.8.3 Reduction of T-cell variation 
Obesity has been linked to a reduced TCR repertoire of circulating T-cells (110). This 
reduces the amount of antigens that can be recognised and responded to. Obesity has also 
been shown to cause a reduction in lymph node size, impair lymphatic fluid transport and 
migration of DCs to peripheral lymph nodes, and reduce the number of T-cells in the 
lymph nodes. These changes reduce the ability of the immune system to recognise and 
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effectively deal with foreign antigens (110). Furthermore, the expansion of adipocytes 
caused by obesity suppresses anti-inflammatory pathways, enabling DCs and T-cells to 
become activated within visceral white adipose tissue. However, constant presentation 
of antigen by DCs may eventually lead to T-cell exhaustion and chronic inflammation, 
reducing the capability for T-cells to have a successful effector response (85). 
1.8.4 Uric acid 
Uric acid in its soluble state is not currently known to have any immunogenic properties. 
However, when crystallised, it can modulate the immune system by acting as a DAMP 
following cell death, although it is not involved in pathogen-related inflammation (121). 
The intracellular environment has a high concentration of soluble uric acid as a result of 
purine catabolism. Furthermore, after cell death, there is an increase in the production of 
uric acid via xanthine oxidase following DNA and RNA degradation. This results in a 
high concentration of uric acid being released into the extracellular fluid when a cell dies, 
often exceeding saturation point (higher than 6.8 mg/dL). The elevated concentration of 
sodium in the extracellular environment then promotes the crystallisation of soluble uric 
acid into monosodium urate (MSU) (121). 
MSU can stimulate the immune system in different ways. Firstly, it can enhance the 
activation of DCs by upregulating the costimulatory molecules CD80/86. MSU has been 
used as an adjuvant in DC vaccinations to successfully increase the generation of CTLs 
(122). It is also known to stimulate monocytes to produce inflammatory mediators (123). 
Finally, MSU has been shown to trigger IL-1β mediated inflammation through activating 
the nucleotide-binding oligomerisation domain-like receptors (NOD)-like receptor 
protein (NLRP)3 inflammasome (124). IL-1β plays an important role in systemic 
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inflammation, promotes neutrophil infiltration, and supports tissue restructuring. It is also 
necessary for the efficient priming of T-cells (125). 
1.9 The effect of metabolic syndrome on immunotherapies 
The vast majority of studies trialling immunotherapy techniques use healthy, lean mice 
as models, and studies looking at the interaction between obesity and cancer 
immunotherapy are lacking. There are very few studies which use hyperuricemic mice 
as models. However, given the effects of obesity and hyperuricemia on the immune 
system, it is hypothesised that an immune-based therapy would not be as efficacious. One 
group has found that the administration of immunotherapy into ob/ob mice (which are 
obese due to being leptin-deficient) compared to lean mice resulted in high levels of 
TNFα, leading to multiorgan pathological responses and rapid lethality. This has been 
attributed to the baseline level of chronic inflammation found in obese mice (126). 
A higher BMI has been shown to be correlated with a greater decline in influenza 
antibody titres 12 months following vaccination compared to healthy weight individuals. 
Furthermore, the obese individuals had decreased CTL activation as well as decreased 
expression of functional proteins, both contributing to a decreased immune response to 
the influenza virus (127). It has also been found that obesity increases the risk of failure 
of other types of vaccines, such as hepatitis B and tetanus (110). Furthermore, DC-based 
immunotherapy in mice with renal cell carcinoma showed regression in lean mice but 
was ineffective in diet-induced obese (DIO) mice. Further investigation found that there 
was an increase in regulatory DCs in the tumour-bearing kidneys and decreased local 
infiltration of CTLs (128). 
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While these are murine models, they demonstrate the impact of obesity on the immune 
system. This both reduces the efficacy of cancer vaccines, as well as increases the 
likelihood of adverse events. 
Conversely, melanoma patients who are classified as overweight or obese have been 
shown to have a better response to anti-PD-1/PD-L1 immune checkpoint inhibitors (129). 
This finding was also replicated in studies where tumour-bearing mice had an increased 
response to anti-PD-L1 treatment if they were obese compared to lean. This phenomenon 
has been postulated to be due to leptin, as increased leptin levels (as seen in obesity) leads 
to greater expression of PD-1 (130). 
Limited research has been performed into the effects of hyperuricemia on 
immunotherapy. However, one study found that melanoma tumour-bearing 
hyperuricemic mice (UrahPlt2/Plt2 strain) had a reduced response to Poly I:C therapy 
compared to wild type mice (131). This may have been due to a reduction in the 
proportion of antigen-specific CD8+ T-cells in these mice. However, they also had a 
greater number of proliferating antigen-specific T-cells in the lymph nodes compared to 
wild type mice. The authors of the study hypothesised that the high background rate of 
division might limit the ability of immunotherapeutic treatments to stimulate an anti-
tumour response (131) 
1.10 Aims and rationale 
Metabolic syndrome is a prevalent and rising problem in our society today. Obesity is a 
known cause of cancer development and progression and has been shown to impair the 
treatment of cancer using traditional techniques. Furthermore, limited research has been 
performed in obese animal models investigating the effect of obesity on cancer 
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immunotherapy. From the studies that have been done, issues around increased toxicity 
and reduced efficacy have been highlighted. 
A previous student in the Young laboratory found that there may be a more 
immunosuppressive environment in obese mice compared to lean mice. Hyperuricemia 
may also impair the activation of the vaccination itself. Following on from this study, it 
has been proposed to research a VLP-based treatment in lean, obese, and hyperuricemic 
mice with breast and colorectal cancer. Specifically, aims are to (i) test the efficacy of a 
standard RHDV VLP vaccine with survivin and MUC1 epitopes in obese and 
hyperuricemic mice compared to lean mice, and (ii) trial a combination with additional 
anti-PD-L1 treatment, which has been shown to increase the efficacy of cancer vaccines 
and may dampen the state of chronic inflammation shown in obesity. Anti-PD-L1 
therapies have not previously been trialled in the Young laboratory. To identify any 
reasons for differences in treatment efficacy observed, TILs will be analysed for the 
frequency of infiltration into the tumours, as well as the expression of markers of 
exhaustion. 
In order to translate results from the murine studies into the patient setting, a case series 
descriptive observational study within the Dunedin colorectal cancer cohort will be 
conducted. This will investigate how obesity and sarcopenia affects 5-year survival 
following cancer resection surgery, and how markers of inflammation vary between 
obesity statuses, something which will also be covered in the murine experiments. CT 
images from the time of diagnosis will be used to determine body composition status, 
rather than relying on BMI as previous studies have done due to the inaccuracies of this 
measure to correctly identify fat mass. Visceral adiposity, which is adipose tissue within 
the abdominal wall, is considered to be a more significant cause of pathologies such as 
cancer and cardiovascular disease (132). Fat in this compartment surrounds the viscera 
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and drains its blood supply via the portal system, and so free-fatty acids entering through 
this route have a more direct effect on the liver than other adipose types (133). Therefore, 
measuring this may give interesting results. 
It is hypothesised that the VLP vaccine alone will be less effective in obese and 
hyperuricemic mice compared to lean mice, but that an increase in the efficacy of 
treatment will be observed when combined with an anti-PD-L1 antibody. Based on 
previous studies, obesity and sarcopenia may cause decreased survival, although 
overweight patients could have an increased survival rate. This study is important as it 
will identify any groups that immunotherapy may work differently in, which is especially 
significant as this technology becomes more widely available.




Materials and Methods 
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2.1 Tumour trials 
2.1.1 Mice 
Male and female specific pathogen-free lean (C57BL/6), obese (C57BL/6NCrl-Leprdb-
lb/Crl, referred to as POUND) and hyperuricemic (UrahPlt2/Plt2) mice aged between 12-
20 weeks old were obtained from the Hercus Taieri Research Unit (HTRU), University 
of Otago, New Zealand (131, 134). Approval for each experimental protocol was 
obtained by the University of Otago Animal Ethics Committee before commencement. 
Approval numbers were DET 17/17 for cell culture work and AUP 18-31 for animal 
work. 
2.1.2 Cell culture 
Breast cancer C57mg.MUC1 (Gendler Lab, Mayo Clinic, Phoenix, AZ, USA) or 
colorectal cancer MC-38 (Vile Lab, Mayo Clinic, MN, USA) cells were grown in large 
tissue culture flasks in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Thermo 
Fisher Scientific, Waltham, MA, USA) + 10% Foetal Calf Serum (FCS) (Moregate 
Biotech, Bulimba, QLD, Australia) + 150 µg/mL geneticin (G418) (Gibco) or DMEM + 
10% FCS respectively (Appendix) (135). At 90% confluency, cells were harvested using 
a solution of 0.002% ethylenediaminetetraacetic acid (EDTA) (Appendix). The cells 
were then spun down with 50 mL sterile Dulbecco’s phosphate-buffered saline (DPBS) 
(Appendix) for 5 minutes at 350 x g at 4ºC and washed with DPBS three times. Cells 
were counted using a 1/20 dilution of 0.4% trypan blue (Appendix) and resuspended in 
DPBS to attain a concentration of 5 x 106 cells/mL (C57mg.MUC1 cells to be injected 
into POUND and C57BL/6 mice), 5 x 107 cells/mL (C57mg.MUC1 cells to be injected 
into UrahPlt2/Plt2 mice) or 6.7 x 105 cells/mL (MC-38 cells to be injected into all mouse 
types). Tumour growth kinetics were performed by a previous laboratory member, who 
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observed that higher concentrations of C57mg.MUC1 cells were needed in order for 
adequate tumour growth in UrahPlt2/Plt2 mice (136). Molecular subtyping was not 
performed on the C57mg.MUC1 cells, although MC-38 cells have been shown to be 
microsatellite instability-high, BRAF+ and KRAS- (137). 
2.1.3 Tumour grafting 
Aliquots of 1 x 105 C57mg.MUC1 cells in a volume of 20 µL were injected into the 
second left mammary fat pad (MFP) of thirty female POUND (in two trials with fifteen 
mice each due to the availability of mice) and C57BL/6 mice. Thirty female UrahPlt2/Plt2 
mice received 1 x 106 cells. Prior to this, C57BL/6 and UrahPlt2/Plt2 mice were injected 
with a Ketamine/Domitor/Atropine mixture subcutaneously (s.c) for inducing 
anaesthesia, placed on heat pads and eye ointment applied. POUND mice were not 
anaesthetised due to safety concerns. Chests were shaved and Nair hair removal cream 
applied with a cotton bud around the nipple area, and then removed 3 minutes later. Mice 
were injected with Antisedan s.c for Domitor reversal and monitored until fully awake. 
Due to a high rate of ulceration in the original fifteen POUND mice, cells in subsequent 
trials were injected into the left fourth MFP as this was thought to rub along the ground 
less. Following suspected pathogen contamination of the C57BL/6 mice, the experiment 
was moved to the Microbiology animal facility and thirty new mice were injected with 
the same amount of cells in the left fourth MFP.  
Aliquots of 1 x 105 MC-38 cells in a volume of 150 µL were injected s.c into the left 
flank of 30 male POUND (two trials of 15 mice each), C57BL/6 and UrahPlt2/Plt2 mice. 
As this was a s.c injection, mice were not required to be anaesthetised. 
After injections, mice were monitored daily until tumours were palpable. Mice were then 
monitored every second day until euthanised. Mice that achieved tumour remission for a 
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minimum of twenty days were regrafted with the same amount of tumour cells on the 
opposite side of the body.  
2.1.4 Preparation of the virus-like particle (VLP) 
The VLP expressing either the survivin and MUC1 epitopes (surv.VLP-SS-MUC1) or 
survivin alone (surv.VLP) has been described in the previous chapter. Katrin Kramer, a 
research fellow in the Young laboratory, manufactured the VLP using a previously 
validated method (138). Particles were checked via Philip CM100 BioTWIN 
Transmission Electron Microscopy (Philips/FEI Corporation, Eindhoven, Netherlands) 
and Mass Spectrometry (Centre for Protein Research, Dunedin, New Zealand) to ensure 
the presence of the relevant epitopes. Before injecting, the VLP concentration was 
confirmed using a NanoDrop 1000 Spectrophotometer, version 3.1 (Thermo Fisher 
Scientific) or a Qubit protein assay (Thermo Fisher Scientific). The VLP was diluted in 
complete PBS (cPBS) (Appendix) to reach a concentration of 0.67 mg/mL 
(corresponding to 100 μg in 150 μL). CpG ODN 1826 (Integrated DNA Technologies, 
Coralville, IA, USA) was added at 0.166 mg/mL (corresponding to 25 μg in 150 μL). 
2.1.5 Treatment injections during tumour challenges 
Once tumours were palpable in all or the majority of mice, mice were distributed into 
three groups with an average approximately equal tumour size. Group one (PBS control) 
was injected with 150 µL cPBS s.c + 10 mg/kg anti-PD-L1 isotype control (Bio X Cell, 
West Lebanon, NH, USA) intraperitoneally (i.p). Group two (VLP only) was injected 
with 150 µL s.c containing 100 µg surv.VLP-SS-MUC1 (breast cancer) or surv.VLP 
(colorectal cancer) + 25 µg CpG, + 10 mg/kg anti-PD-L1 isotype control i.p. Group three 
(VLP + anti-PD-L1) was injected with 150 µL s.c containing 100 µg surv.VLP-SS-
MUC1 or surv.VLP + 25 µg CpG, + 10 mg/kg anti-PD-L1 (Bio X Cell) i.p. Mice were 
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then injected with either the anti-PD-L1 isotype control or anti-PD-L1 at 10 mg/kg i.p 
three days and six days later. Once tumours had reached 150 mm2 or ulcerated, mice 
were euthanised via cervical dislocation and tumours were either preserved for 
histological staining or tumour-draining lymphocytes (TILs) were prepared for flow 
cytometric analysis. 
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2.2 Investigating tumour-infiltrating lymphocytes 
2.2.1 Immunohistochemical analysis of tumours 
Mice were euthanised, secured on a dissection stage and heavily sprayed with 70% 
ethanol. Tumours were removed using sterile scissors and tweezers and preserved in 
formalin (Sigma-Aldrich, St Louis, MO, USA) for 24 hours. Tumours were then kept in 
70% absolute ethanol (Lab Supply Ltd, Dunedin, New Zealand) until prepared and 
stained with Gill’s haematoxylin and alcoholic eosin (H&E) (Surgipath, Leica 
Biosystems, Wetzlar, Germany), and cluster of differentiation (CD)3 antibody (Abcam, 
Cambridge, UK) at a 1 in 150 dilution, which contained a 3,3′-Diaminobenzidine (DAB) 
substrate. This was performed by a Medical Laboratory Scientist within the Otago 
Histology Services Unit. Slides were scanned using Aperio ScanScope slide scanner 
(Leica Biosystems) and Scanner Console, version 102.0.7.5. Images were loaded onto 
Aperio ImageScope, version 12.4.0, and exported into TIFF format. Images were further 
analysed using ImageJ (National Institutes of Health, USA), version 1.52a. 
To measure the area of each cross-section, a freehand selection line was drawn around 
the border of each tumour. Tumours were then split into inner and outer tumour regions, 
defined by a 250 µm width margin from the outer border. Area measurements were taken 
at this point. The different components of the histological stain were then separated and 
the DAB component selected. The image was converted to black-and-white and 
individual cells defined in order to be able to be read and counted by the software (Figure 
3). This process was repeated for whole tumour, inner tumour and outer tumour images. 
  













Figure 3: Analysis of CD3 immunohistochemical staining 
A) Tumour isolated from the background and split into whole tumour, inner tumour and outer tumour 
regions 
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2.2.2 Isolation of Tumour Infiltrating Lymphocytes (TILs) 
Mice were euthanised, secured on a dissection stage and heavily sprayed with 70% 
ethanol. Tumours, spleens and lymph nodes (tumour draining and non-tumour draining) 
if possible were removed using sterile scissors and tweezers and placed in cold Roswell 
Park Memorial Institute (RPMI) 1640 + GlutaMAX™ (Gibco) media. To create single-
cell suspensions, samples were processed using the plunger from a 5 mL syringe and 
filtered through a 100 µm strainer followed by a 70 µm strainer. Single-cell suspensions 
were layered onto Ficoll-Paque™ PLUS (GE Healthcare Bio-Sciences AB, Uppsala, 
Sweden) using a transfer pipette to isolate the white blood cells and centrifuged for 20 
minutes at 800 x g, acceleration 3, brake 0, at 20℃. This technique causes white blood 
cells to become suspended in an intermediate layer known as the buffy coat, which was 
transferred into a falcon tube and washed with DPBS. An aliquot of 3 mL warm red blood 
cell (RBC) lysis buffer (Appendix) was added to the isolated splenocytes for 3 minutes 
in order to lyse RBCs. Cells were washed with DPBS. 
To stain for live cells, samples were stained with 50 µL Zombie Yellow™ viability dye 
(Table 1) diluted 1/200 in DPBS for 15 minutes in the dark at room temperature. Cells 
were then washed in 2 mL Fluorescence-Activated Cell Sorting (FACS) buffer 
(Appendix) and centrifuged for 3 minutes at 350 x g at 4℃. To prevent non-specific 
staining of antibodies, 50 µL Fc block (Table 1) diluted 1/200 in FACS buffer was added 
to each sample and incubated for 5 minutes at 4℃. Antibodies against T-cell lineages 
(CD3, CD4, CD8) and markers of T-cell exhaustion, PD-1, LAG-3, Tim-3, CD127, and 
CD39 (Table 1) were used to phenotype T-cells. Antibodies diluted in 50 µL FACS 
buffer were added to the cells and incubated for 15 minutes at 4℃. Cells were then 
washed with 1 mL FACS buffer and centrifuged for 3 minutes at 350 x g at 4℃. Cells 
were resuspended in 200 µL FACS buffer and analysed by flow cytometry.  
Materials and Methods  Matthew J. Woodall 
42 
 
If samples were not to be analysed the same day, cells were incubated in 200 μL 2% 
paraformaldehyde (Appendix) and incubated for 15 minutes in the dark at room 
temperature. Samples were washed with 1 mL FACS buffer and centrifuged for 3 minutes 
at 350 x g at 4℃. Cells were resuspended in 200 μL FACS buffer, covered in Parafilm 
(Bemis, Neenah, WI, USA) and stored at 4℃. 
2.3 Isolation of immune cell populations from the blood of tumour-bearing mice 
In order to examine how the immune cell populations in the blood changed over time 
during treatment, blood from C57BL/6 and POUND mice injected with MC-38 cells was 
collected. Tails of five mice were tipped and 4-5 drops of blood collected into 1 mL 
Alsever’s solution (to prevent clotting) (Appendix) before injection of tumour cells and 
before initiation of treatment. The blood of five mice per treatment group was then 
collected weekly until the end of the trial. Samples were centrifuged for 5 minutes at 350 
x g at 4℃. An aliquot of 3 mL RBC lysis buffer was added to the samples and incubated 
for 2 minutes. Samples were washed two times with DPBS before commencing standard 
FACS staining procedures as described previously (section 2.2.2). Antibodies against 
Ly6G, Ly6C, CD11c, B220, CD8, CD4 and CD3 were used (Table 1). 
2.4 Flow cytometric analysis 
All samples were analysed by flow cytometry using a Gallios™ flow cytometer 
(Beckman Coulter, Brea, CA, USA). 100,000 events per sample were collected for TIL 
staining, and at least 10,000 events per sample for blood staining. Data was analysed 
using Kaluza analysis software (Beckman Coulter, Brea, CA, USA), version 2.1. 
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Table 1: antibodies used in flow cytometry 
Anti-mouse 
antibodies 
Fluorophore Concentration Dilution Clone Supplier 
CD11b APC 0.2mg/mL 1:400 M1/70 Biolegend 
CD11c PE 0.2mg/mL 1:100 N418 Biolegend 




None 0.5mg/mL 1:200 2.4G2 BD 
Biosciences 
CD223 PE 0.2mg/mL 1:100 C9B7W BD 
Biosciences 
CD279 (PD-1) FITC 0.5mg/mL 1:100 29F.1A12 Biolegend 
CD279 (PD-1) PerCP/Cy5.5 0.2mg/mL 1:100 29F.1A12 Biolegend 
CD3  BV421 0.2mg/mL 1:200 17A2 Biolegend 
CD366 APC 0.2mg/mL 1:100 RMT3-23 Biolegend 
CD39 PE/Cy7 0.2mg/mL 1:100 Duha59 Biolegend 
CD4 APC-H7 0.2mg/mL 1:200 GK1/5 BD 
Biosciences 
CD45R/B220 PE/Dazzle™594 0.2mg/mL 1:100 RA3-
GB2 
Biolegend 
CD45R/B220 PerCP/Cy5.5 0.2mg/mL 1:100 RA3-6B2 Biolegend 
CD8a AF700 0.5mg/mL 1:200 53-6.7 Biolegend  
Live/Dead Zombie 
YellowTM 
 1:200  Biolegend 
Ly-6C PE/Cy7 0.2mg/mL 1:400 HK1.4 Biolegend 
Ly-6G FITC 0.5mg/mL 1:200 1A8 BD 
Biosciences 
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2.5 Descriptive observational study: the effect of body composition on cancer 
outcomes 
2.5.1 Inclusion criteria 
Patients enrolled in the Dunedin colorectal cancer cohort were identified using the Health 
Research Council Colorectal Cancer (HRC CRC) database. Patients that had surgeries 
between January 2008 and June 2014 were selected to maximise the likelihood of having 
a computerised tomography (CT) scan at diagnosis being available as well as allowing at 
least five years of follow-up time. Those diagnosed with stage I or II colorectal cancer 
were chosen as their body compositions were less likely to have been modified by cancer. 
Finally, patients in the Southern District Health Board electronic record system Health 
Connect South database with National Health Index (NHI) numbers that were no longer 
registered, those who were duplicated, or those without a CT scan around the time of 
diagnosis were excluded (Figure 4). 
  




Figure 4: Inclusion criteria 
Out of the 1529 patients enrolled in the study, 353 patients had their cancer resection surgeries between 
January 2008 and June 2014. Of these, 155 patients had stage I or II colorectal cancer. After removing 
patients either not on the database, duplicates, or those without a diagnostic CT scan, 136 patients were 
included in the study.  
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2.5.2 CT analysis 
The body composition factors fat mass and muscle mass were investigated as these are 
significant for the health outcomes of a variety of diseases (139). To split the data into 
groups based on obesity status, height and weight were recorded and BMI calculated. 
However, as many patients did not have online records of these measurements, and due 
to the inaccuracy of BMI to accurately reflect obesity status, pre-operative CT scans 
performed at the time of diagnosis were used to calculate fat mass and waist 
circumference. Abdominal CT scans (field of view of 368 mm, slice thickness of 5 mm, 
120 kVp, 425 mAs) were selected and the intervertebral disc between the level of the 
third and fourth lumbar vertebra (L3/4) was identified using a pre-programmed spinal 
level tool as well as using the anatomical landmarks of the iliac crest and aortic 
bifurcation which occur at the level of L4. This level has been shown to be a good 
representation of overall fat mass (140). To calculate the total fat area, a line was drawn 
around the skin using the software Syngo.via (Siemens Healthineers, Erlangen, 
Germany). The Anatomy Visualiser tool was used to measure the cross-sectional area of 
fat, thresholded by the Hounsfield values of -150 to -50. To determine visceral fat area 
this process was repeated, however, the line was drawn around the inner layer of 
abdominal wall muscles (Figure 5A). 
CT scans were used at the level of L3 to measure waist circumference (141). Using the 
distance polyline tool, a freehand line was drawn around the skin, giving the waist 
circumference in centimetres (Figure 5B). Waist circumferences measured on CT have 
been shown to be equivalent to those measured by a health professional while the patient 
is standing (142). 
To measure skeletal muscle mass, CT scans were used at the level of L3 (143). Rectus 
abdominis, transverse adbominis, external and internal oblique muscles, psoas, quadratus 
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lumborum and erector spinae were identified and a line drawn around them. A Hounsfield 
threshold of -29 to 150 was used. This was normalised by dividing by height (in m2) 
(144). 
Both skeletal muscle and fat mass calculations were measured as a volume with the units 
of cm3. In order to convert this to the surface area, measurements were divided by slice 
thickness (145). 

















Figure 5: Measuring body composition using CT 
A) Using the Anatomy Visualiser tool on Syngo.via, freehand lines were drawn around the skin and 
abdominal muscle wall at the intervertebral disc between L3/4, and around the abdominal muscles at L3. 
Hounsfield values of -150 to -50 for fat, and -29 to 150 for muscles were then used as a threshold to identify 
either fat or muscle. Volumetric measurements were taken, which were divided by the slice thickness in 
order to get the cross-sectional area for total fat, visceral fat, and lumbar skeletal muscle mass. 
B) Using the distance polyline tool, a freehand line was drawn around the skin at the level of L3 in order 
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2.5.3 Patient data collection 
Data was collected using Health Connect South. NHI numbers were used to identify 
blood tests performed up to three months before tumour resection date. The following 
parameters were collected from the patient where possible: complete blood count 
(including haemoglobin, platelets, white blood cell (WBC), neutrophil, lymphocyte, 
monocyte, eosinophil and basophil levels), albumin and total protein, C-reactive protein 
(CRP), erythrocyte sedimentation rate (ESR), and carcinoembryonic antigen (CEA) 
levels. Sex, smoking status, age and 5-year survival from the date of surgical resection 
were also recorded. This study comes under that of the Dunedin colorectal cancer cohort, 
ethics number 14/NTA/33. 
2.6 Statistical analysis for all data 
Five mice per group were used for TIL phenotyping and blood immune cell isolation and 
then pooled in one graph to show the consistency of the results. Two mice per group were 
used for TIL frequency due to the time-consuming nature of the analysis. Data was 
expressed as mean ± standard error of the mean (SEM). All data was tested for normality 
using the Shapiro-Wilks test. Normally distributed means were compared using unpaired 
student’s t-test or one-way analysis of variance (ANOVA) followed by post hoc Tukey’s 
pairwise comparison. If data was not normally distributed, a Kruskal-Wallis test was 
performed followed by post hoc Dunn’s pairwise comparison. Kaplan-Meier survival 
curves were analysed using the Mantel-Cox test. 
Appropriate sample sizes were determined using a power analysis with a signal-to-noise 
statistic of 1.35. Using 5% significance at 80% power, this confirmed that a sample size 
of n=10 mice per group for the tumour trials was required. Power calculations were 
unable to be performed prior to starting the colorectal cancer patient cohort research as 
the number of patients possible to use was unknown. Therefore, the intent of the research 
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in this section was to general hypotheses and determine whether this type of analysis was 
possible in this cohort.
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3.1 Tumour growth and survival rates in lean, obese and hyperuricemic mice 
3.1.1 Immunotherapeutic treatment of cancer in obese mice 
3.1.1.1 Breast cancer 
To see if obesity had an impact on the efficacy of VLP treatment of breast cancer, thirty 
female POUND +/+ mice were injected with 1 x 105 C57mg.MUC1 cells in two 
individual experiments. The trial was split in half (fifteen mice per experiment) due to 
the availability of POUND mice. The first fifteen mice had cells injected into the second 
left MFP. After significant ulceration problems (3/4, 4/5 and 3/5 tumours in the PBS, 
VLP and VLP + anti-PD-L1 groups respectively), it was decided that further experiments 
would involve injecting cells into the fourth left MFP as tumours in this area would rub 
against the ground less. Tumours were palpable on day 7 for the first trial and day 6 for 
the second. At this time, mice were treated with either PBS + an isotype control of anti-
PD-L1, surv.VLP-SS-MUC1 + isotype control, or surv.VLP-SS-MUC1 + anti-PD-L1. 
Results from the two trials differed. In the first trial, compared to control, treatment with 
VLP alone did not result in tumour remission although survival was increased. While 
tumour growth curves were similar, the median survival for the VLP group was 59 days 
as opposed to 47.5 days in the PBS group. The combination therapy of VLP + anti-PD-
L1 resulted in tumour remission for 2/5 mice. One mouse remained tumour free for over 
50 days and did not show tumour growth after rechallenge with the same cancer cells. 
Median survival for this group was 145 days (Figure 6A). 
Due to the high number of ulcerations in this trial, data from ten mice had to be censored, 
so these observations were only in a limited number of mice. This also resulted in the 
large standard error as shown in the tumour growth graph (Figure 6A). 
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In the second trial, there was no difference in tumour growth rates between treatment 
groups. Survival curves show that the VLP and VLP + anti-PD-L1 groups survived 
longer than the PBS control group, however median survivals times for PBS and VLP + 
anti-PD-L1 groups were 46 and 50 days respectively. The median survival for the VLP 
group was extended compared to the other two groups at 70 days (Figure 6B). 1/5 
tumours from the PBS group, and 1/5 tumours from the VLP group, ulcerated. 
  




Figure 6: Tumour growth and survival curves for obese mice injected with C57mg.MUC1 cells 
Mice aged between 12-20 weeks were injected with 1 x 105 C57mg.MUC1 cells and given a treatment of 
either PBS s.c + isotype control i.p, VLP s.c + isotype control, or VLP + anti-PD-L1 i.p once tumours 
became palpable. Mice were weighed and tumours measured every two days until tumours reached 
150 mm2 or ulcerated, after which they were culled. A) trial one involving fifteen POUND +/+ mice, B) 
trial two involving fifteen POUND +/+ mice.  
The results for tumour growth rates represent the mean (± SEM) of five mice per treatment group. Mice 
with ulcerated tumours were censored at the date of termination. Statistical differences were determined 
using a Mantel-Cox test. 
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3.1.1.2 Colorectal cancer 
In order to investigate the effects of obesity on the efficacy of VLP vaccine treatment of 
colorectal cancer, fifteen male POUND +/+ mice were injected with 1 x 105 MC-38 cells 
s.c into the left flank. Once tumours were palpable (day 8 for the first trial and day 7 for 
the second trial), mice were divided into three groups with approximately equal tumour 
size. Mice were treated with either PBS + an isotype control of anti-PD-L1, surv.VLP + 
isotype control, or surv.VLP + anti-PD-L1. 
There was no difference in growth rates or survival time in any of the treatment groups, 
and by day 30 all mice had been culled due to reaching the specified surface area 
(150 mm2), with a small number of tumours ulcerating (Figure 7A). Median survival for 
the PBS and VLP + anti-PD-L1 groups was 25 days, and for the VLP only group was 27 
days. 2/5 and 2/5 tumours in the VLP and VLP + anti-PD-L1 groups respectively 
ulcerated. 
In the second trial, fifteen male POUND mice were injected with 1 x 105 MC-38 cells. 
Tumours grew slower in the VLP and VLP + anti-PD-L1 groups compared to the PBS 
group, although tumours in the two treatment groups grew at a similar rate (Figure 7B). 
Survival rates for the three groups showed a difference between each, with a median 
survival of 25 days for PBS, 34 days for VLP and 39 days for VLP + anti-PD-L1, which 
was statistically significant between the PBS and VLP + anti-PD-L1 groups (p = 0.0014). 
Respectively, 1/5, 2/5 and 1/5 tumours in the PBS, VLP and VLP + anti-PD-L1 groups 
ulcerated. 
  




Figure 7: Tumour growth and survival curves for obese mice injected with MC-38 cells 
Mice aged between 12-20 weeks were injected with 1 x 105 MC-38 cells and given a treatment of either 
PBS s.c + isotype control i.p, VLP s.c + isotype control, or VLP + anti-PD-L1 i.p once tumours became 
palpable. Mice were weighed and tumours measured every two days until tumours reached 150 mm2 or 
ulcerated, after which they were culled. A) trial one involving fifteen POUND +/+ mice, B) trial two 
involving fifteen POUND +/+ mice.  
The tumour growth results represent the mean (± SEM) of five mice per treatment group. Mice with 
ulcerated tumours were censored at the date of termination. Statistical differences were determined using 
a Mantel-Cox test. ** p ≤ 0.01 
Results  Matthew J. Woodall 
57 
 
3.1.2 Immunotherapeutic treatment of cancer in hyperuricemic mice 
3.1.2.1 Breast cancer 
To investigate the effects of hyperuricemia on the efficacy of VLP vaccine treatment of 
breast cancer, thirty female UrahPlt2/Plt2 mice were injected with 1 x 106 C57mg.MUC1 
cells into the second left MFP. Tumours became palpable on day 5, and mice were treated 
as described previously. 
Tumours in all three groups grew at the same rate and no tumour remission was observed. 
Mice treated with VLP and VLP + anti-PD-L1 had a superior median survival of 55 and 
53 days respectively, with the PBS group having a median survival of 46 days (Figure 
8). However, this difference was not statistically significant. Ulcerations occurred in 
3/10, 6/10 and 4/10 tumours in the PBS, VLP and VLP + anti-PD-L1 groups respectively. 
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Figure 8: Tumour growth and survival curves for hyperuricemic mice injected with C57mg.MUC1 
cells 
Mice aged between 12-20 weeks were injected with 1 x 106 C57mg.MUC1 cells and given a treatment of 
either PBS s.c + isotype control i.p, VLP s.c + isotype control, or VLP + anti-PD-L1 i.p once tumours 
became palpable. Mice were weighed and tumours measured every two days until tumours reached 
150mm2 or ulcerated, after which they were culled. 
The tumour growth results represent the mean (± SEM) of ten mice per treatment group. Mice with 
ulcerated tumours were censored at the date of termination. Statistical differences were determined using 
a Mantel-Cox test. 
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3.1.2.2 Colorectal cancer 
Investigation into the effects of hyperuricemia on the efficacy of VLP vaccine treatment 
on colorectal cancer involved injecting 30 male UrahPlt2/Plt2 mice with 1 x 105 MC-38 
cells s.c into the left flank. Treatment on day 8 with either VLP alone or in combination 
with anti-PD-L1 did not result in a regression of tumour sizes (Figure 9). Survival was 
reduced in the PBS group, with a median survival of 30 days respectively. Mice in the 
VLP and VLP + anti-PD-L1 groups survived slightly longer, with a median survival of 
35 days, although this was not statistically significant (Figure 9). After excluding mice 
that did not develop tumours, 2/8 and 3/9 tumours from the PBS and VLP groups 
respectively ulcerated. 
  




Figure 9: Tumour growth and survival curves for hyperuricemic mice injected with MC-38 cells 
Mice aged between 12-20 weeks were injected with 1 x 105 MC-38 cells and given a treatment of either 
PBS s.c + isotype control i.p, VLP s.c + isotype control, or VLP + anti-PD-L1 i.p once tumours became 
palpable. Mice were weighed and tumours measured every two days until tumours reached 150 mm2 or 
ulcerated, after which they were culled. 
The tumour growth results represent the mean (± SEM) of 10 mice per treatment group. Mice with 
ulcerated tumours were censored at the date of termination. Statistical differences were determined using 
a Mantel-Cox test. 
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3.1.3 Immunotherapeutic treatment of cancer in lean mice 
3.1.3.1 Breast cancer 
To compare the efficacy of the VLP or VLP + anti-PD-L1 treatment in obese and 
hyperuricemic mice, lean mice were used as a positive control as they have previously 
shown to respond to the VLP treatment. Thirty female POUND -/- mice were injected 
with 1 x 105 C57mg.MUC1 cells into the second left MFP. Tumours were palpable on 
day 6 and mice were treated as before. 
Initially, tumours grew at a linear rate and mice injected with either VLP or VLP + anti-
PD-L1 diverged with slower-growing tumours from the PBS control group at 
approximately day 14. However, for reasons unknown, between days 14 and 36 tumour 
growth in the control group plateaued, after which all groups grew at a similar rate 
(Figure 10A). 
Survival during this time was the same for all groups. Tumours from the control group 
did not grow in a linear fashion, which was not expected and had not previously been 
observed. Therefore, we were unable to make a comparison of treatment efficacy 
between groups, and it was decided that all mice would be culled, and the trial repeated. 
At this time, the Young laboratory had several other tumour trials housed in the Hercus 
Taieri Animal Facility that experienced similar issues. It was decided to shift all trials to 
the Microbiology animal facility. 
In the repeat trial, C57BL/6 mice were used instead of POUND -/- mice as this strain 
could not be transferred between buildings. POUND mice come from the same genetic 
background, so the two strains of mice were considered to be synonymous with each 
other. Cells were injected into the fourth left MFP. 
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Tumours were palpable at day 8 and treatment injections were given at this time. Growth 
curves were similar for the PBS and VLP groups, with a median survival of 77 days for 
both. Mice injected with VLP + anti-PD-L1 had a slowed tumour growth, with a 
significantly prolonged median survival of 128 days (p = 0.0004) (Figure 10B). Three 
mice in this group achieved tumour remission. After 50 days of tumour-free survival, the 
mice were rechallenged with the same amount of tumour cells. Tumour remission was 
sustained following this, and no mice grew new tumours. After 50 more days, the mice 
were culled. Tumour growth in all groups was slower than in previous trials investigating 
C57mg.MUC1 cell growth rates in C57BL/6 mice, with the first mouse reaching 
150 mm2 at day 65 (Figure 10B). Ulcerations occurred in 2/10, 4/10 and 5/10 tumours in 
the PBS, VLP, and VLP + anti-PD-L1 groups respectively. These mice were censored 
from the survival curve at the date of termination. 
  




Figure 10: Tumour growth and survival curves for lean mice injected with C57mg.MUC1 cells 
Mice aged between 12-20 weeks were injected with 1 x 105 C57mg.MUC1 cells and given a treatment of 
either PBS s.c + isotype control i.p, VLP s.c + isotype control, or VLP + anti-PD-L1 i.p once tumours 
became palpable. Mice were weighed and tumours measured every two days until tumours reached 
150 mm2 or ulcerated, after which they were culled. A) trial one involving thirty female POUND -/- mice 
which were terminated after PBS-treated tumours failed to grow, B) trial two involving thirty female 
C57BL/6 mice.  
The tumour growth results represent the mean (± SEM) of ten mice per treatment group. Mice with 
ulcerated tumours were censored at the date of termination. Statistical differences were determined using 
a Mantel-Cox test. *** p ≤ 0.001 
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3.1.3.2 Colorectal cancer 
To assess the efficacy of VLP vaccine treatment against colorectal cancer in lean mice, 
thirty male C57BL/6 mice were injected with 1 x 105 MC-38 cells s.c into the left flank. 
Tumours were palpable on day 7 and treatments were given as before. Tumour growth 
rates in all groups were the same and median survival was 31 days for all groups. 1/10 
mice in the VLP group and 1/10 mice in the VLP + anti-PD-L1 group were able to 
achieve remission which was sustained following tumour rechallenge (Figure 11). Only 
one tumour, in the VLP + anti-PD-L1 group, ulcerated. 
Figure 11: Tumour growth and survival curves for lean mice injected with MC-38 cells 
Mice aged between 12-20 weeks were injected with 1 x 105 MC-38 cells and given a treatment of either 
PBS s.c + isotype control i.p, VLP s.c + isotype control, or VLP + anti-PD-L1 i.p once tumours became 
palpable. Mice were weighed and tumours measured every two days until tumours reached 150 mm2 or 
ulcerated, after which they were culled.  
The tumour growth results represent the mean (± SEM) of ten mice per treatment group. Mice with 
ulcerated tumours were censored at the date of termination. Statistical differences were determined using 
a Mantel-Cox test. 
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3.2 Analysis of tumour-infiltrating lymphocytes 
3.2.1 Analysis of immunohistochemical staining of tumours 
In order to determine why many of the tumour trials had unexpected results, a preliminary 
study to investigate the infiltration frequency of TILs in the tumours was undertaken. 
Half of the tumours from all tumour trials were preserved in formalin and stained for 
CD3+ cells, allowing us to see the distribution and frequency of TILs. Slides were 
analysed using ImageJ and tumours divided into outer tumour and inner tumour regions. 
Only two tumours per group were analysed, so this low sample number meant that 
statistical analysis was not performed. 
3.2.1.1 Breast cancer 
In all mouse breeds, there was a trend of no difference in TIL frequency between PBS, 
VLP or VLP + anti-PD-L1 treatment groups. This was the same for the outer part of the 
tumour and the inner segment, as well as the tumour as a whole. 
However, there were trends of differences between mouse breeds. In all treatment groups, 
there appears to be greater infiltration of both the inner and outer tumour by T-cells in 
lean mice, with obese mice having the smallest frequency. Hyperuricemic mice had a 
frequency that is in between that of obese and lean mice in all parts of the tumour (Figure 
12A). The exception for these findings was in hyperuricemic mice treated with VLP only, 
where there was an increase in the frequency of TILs in the outer tumour. 
3.2.1.2 Colorectal cancer 
All mice grafted with colorectal cancer and treated with VLP had an increase in the 
number of TILs in the outer part of the tumours. This difference was most pronounced in 
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hyperuricemic and obese mice. There were no other differences in TIL frequency 
between treatment groups in any mouse type. 
When comparing TIL frequency between mice breeds, the trend observed was that obese 
and lean mice treated with PBS and VLP + anti-PD-L1 had similar levels of TILs, while 
hyperuricemic mice had a lower frequency. When treated with VLP, obese mice had the 
greatest numbers of TILs, with hyperuricemic mice also having an increase in TIL 
frequency compared to the PBS-treated mice. Lean mice had the lowest frequency of the 
three mouse types (Figure 12B).  




Figure 12: Frequency of TILs in C57mg.MUC1 and MC-38 tumours based on treatment group 
Two tumours per mice were preserved in formalin per treatment group per mouse strain and stained for 
CD3. Images were then analysed using ImageJ and cell number divided by the area of the tumour in 
microns2. A) C57mg.MUC1 tumours, B) MC-38 tumours. The results represent the individual values (± 
SEM) of two mice per treatment group. Due to the low sample number, statistical analysis was not 
performed. 
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3.2.2 Phenotyping TILs for markers of exhaustion 
To phenotype the TILs, tumours, spleens, tumour-draining lymph nodes and non-tumour-
draining lymph nodes were removed from half of the lean and obese mice and processed. 
Samples were stained and analysed by flow cytometry. CD3 was used to detect the T-
cells, which were further divided into CD4+ and CD8+ T-cells. Surface markers PD-1, 
LAG-3, Tim-3, CD127, and CD39 were used to phenotype T-cells for exhaustion. Figure 
13 shows the gating strategy used to isolate specific cell populations. This was performed 
for C57BL/6 and POUND mice. 
  




Figure 13: Gating strategy for phenotyping of tumour-infiltrating lymphocytes 
POUND and C57BL/6 mice were injected with 1 x 105 MC-38 or C57mg.MUC1 cells and then treated 
with either PBS, VLP, or VLP + anti-PD-L1. Once tumours reached the defined endpoint (150 mm2 or 
ulceration), mice were culled and tumours, spleens, tumour-draining lymph nodes and non-tumour-
draining lymph nodes were harvested and stained with fluorophore-conjugated antibodies against different 
receptors. Cells were gated based on size (forward scatter) and granularity (side scatter) in order to exclude 
doublet cells, and with Zombie Yellow Live/Dead viability staining to exclude dead cells. Cells were 
labelled with fluorophore-conjugated antibodies against PD-1, LAG-3, CD127, CD39, Tim-3, CD8, CD4 
and CD3.  
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3.2.2.1 Breast cancer 
Overall PD-1 expression in tumour-bearing lean and obese mice was high, indicating that 
there was some level of exhaustion in both CD8+ and CD4+ T-cells (Figure 14A, F). In 
lean mice, the frequency of CD4+ PD-1+ T-cells was reduced in the VLP compared to the 
PBS group, and in the VLP + anti-PD-L1 group compared to the VLP group. This was 
not statistically significant (Figure 14A). CD8+ T-cells in the PBS and VLP groups 
expressed similar levels of PD-1, however, mice treated with VLP + anti-PD-L1 had 
lower levels (Figure 14F). Levels did not differ between treatment groups in the obese 
mice. There was a trend towards a higher expression of PD-1 in obese mice compared to 
lean mice, with there being significantly higher levels of PD-1+ CD8+ T-cells in the obese 
mice compared to the lean mice treated with VLP + anti-PD-L1 (p = 0.0314).  
Tumour specific but terminally exhausted T-cells can be characterised by being PD-1+ 
CD39+ (146). The frequencies of CD8+ T-cells expressing these markers were similar in 
all obese treatment groups and similar for lean mice in the PBS and VLP groups (Figure 
14B, G). Lower frequencies of tumour-specific CD4+ and CD8+ T-cells were detected in 
the VLP + anti-PD-L1 treated lean mice. Differences between mice strains were not 
statistically significant. 
CD127, which is the α-chain of the IL-7 receptor and is important in long term persistence 
of T-cells in the absence of antigen, has reduced expression in exhausted T-cells (32). 
Differences between treatment groups and mouse strains were not significant except 
between CD8+ T-cells in the VLP and VLP + anti-PD-L1 groups in lean mice (Figure 
14C, H). In this group, VLP-treated mice had significantly higher numbers (p = 0.0387), 
indicating a lower level of exhaustion. 
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T-cells which are terminally exhausted are PD-1+ as well as Tim-3+ or LAG-3+. There 
were statistically significantly more PD-1+ LAG-3+ CD4+ T-cells in obese mice 
compared to lean mice (p = 0.0331), and there was the same trend in CD8+ T-cells (Figure 
14D, I). Differences between treatment groups were not significant. The frequencies of 
PD-1+ Tim-3+ T-cells were the opposite, whereby there were greater numbers of these 
cells for all treatments groups in the lean mice than the obese mice, which was 
statistically significant in CD4+ T-cells (p = 0.0308) (Figure 14E, J). Differences between 
treatment groups were not significant. 
When comparing the expression of PD-1, CD39, LAG-3 and Tim-3 in TILs, as opposed 
to those located in the spleen, expression in the splenocytes was reduced in all cases. 
Expression of CD127 was increased in splenocytes for the majority of treatment groups. 
There was no significant difference between treatment groups or mouse strains, although 
there was a trend of an increase in the overall expression of PD-1, LAG3 and Tim-3 in 
obese mice compared to lean mice (Supplementary Figure 1, Appendix). 
  




Figure 14: Markers of T-cell exhaustion in C57mg.MUC1 tumours 
The results represent the mean (± SEM) of five mice per treatment group. Statistical differences were 
determined by using a one-way ANOVA. * p ≤ 0.05. 
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3.2.2.2 Colorectal cancer 
Analysis of the results from MC-38 tumours showed no statistically significant 
differences between treatment groups or mouse strains. The majority of TILs in MC-38 
tumours expressed PD-1, indicating some level of exhaustion in most T-cells. PD-1 
expression in CD4+ T-cells was the same between obese and lean mice and between 
treatment groups (Figure 15A). PD-1 expression in CD8+ T-cells was the same between 
mouse types, however, there was a trend of PD-1 expression being lower in the PBS 
groups (Figure 15F). 
Differences in the frequencies of PD-1+ CD39+ (tumour specific, terminally exhausted) 
T-cells were not significant between obese and lean mice for both CD4+ and CD8+ T-
cells (Figure 15B, G). For both subsets of T-cells, expression of these markers tended to 
be higher in the VLP and VLP + anti-PD-L1 treatment groups. 
CD127 expression, which is reduced in exhausted T-cells, had no difference in frequency 
between treatment groups in obese mice. However, in lean mice the VLP treated group 
trended towards a higher amount of these cells than the PBS and VLP + anti-PD-L1 
groups for both CD4+ and CD8+ T-cells (Figure 15C, H).  
The frequency of terminally exhausted CD4+ T-cells which are PD-1+ LAG-3+ did not 
differ in lean mice across treatment groups (Figure 15D). Obese mice treated with VLP 
alone showed a trend towards slightly reduced numbers of PD-1+ LAG-3+ CD4+ T-cells. 
In general, obese mice had a higher frequency of PD-1+ LAG-3+ CD4+ T-cells.  
In the CD8+ T-cell population, both obese and lean mice had similar levels of PD-1+ 
LAG-3+ cells (Figure 15I). VLP and VLP + anti-PD-L1 treated groups had a trend of 
higher frequencies of these cells in lean mice, and the VLP + anti-PD-L1 treated group 
had a trend of a higher frequency in the obese mice.  
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PD-1+ Tim-3+ CD4+ and CD8+ T-cells had similar frequencies in both mouse types 
(Figure 15E, J). The two treatment groups tended to have higher frequencies of these 
cells compared to the PBS group in both lean and obese mice. 
These markers highlight a trend that in MC-38 tumours, groups treated with VLP or VLP 
+ anti-PD-L1 tended to have a higher level of exhausted TILs compared to the control. 




Figure 15: Markers of T-cell exhaustion in MC-38 tumours 
The results represent the mean (± SEM) of four mice per treatment group, except for C57BL/6 mice treated 
with PBS and VLP + anti-PD-L1, which had five mice. Statistical differences were determined by using a 
one-way ANOVA. 
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3.3 Frequencies of circulating immune cells in lean and obese mice 
To follow the expansion of immune cell populations in the blood during immunotherapy 
treatment, C57BL/6 and POUND mice grafted with MC-38 cells were tail bled every 7 
days. Treatments (PBS, VLP or VLP + anti-PD-L1) were injected on days 7-13. Samples 
were then FACS stained and analysed via flow cytometry. Cell populations stained for 
were T-cells (CD4+ and CD8+), B-cells (CD3- B220+), inflammatory monocytes (CD3- 
B220- CD11b+ Ly6C+ Ly6G-), neutrophils (CD3- B220- CD11b+ Ly6C+ Ly6G+), and 
myeloid- and lymphoid-derived DCs (CD3- B220- CD11c+ CD11b+ or CD11b- 
respectively). Figure 16 shows the gating strategy used to identify these cell types. 
Samples were taken until the majority of mice per group were culled, until day 28 in 
POUND mice (except for the PBS group which was until day 21), and day 35 in C57BL/6 
mice. 
  




Figure 16: Gating strategy to identify immune cell populations in the blood 
POUND and C57BL/6 mice were injected with 1 x 105 MC-38 cells and then treated with either PBS, VLP, 
or VLP + anti-PD-L1. Every 7 days mice were tail bled and stained with fluorophore-conjugated antibodies 
against different immune cell markers. After exclusion of debris, cells were gated based on size (forward 
scatter) and granularity (side scatter) to exclude doublet cells, and with Zombie Yellow Live/Dead viability 
staining to exclude dead cells. Cells were labelled with fluorophore-conjugated antibodies against Ly6G, 
CD11c, B220, Ly6C, CD11b, CD8, CD4 and CD3.  
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Differences in several cell populations were detected in lean and obese mice types. The 
frequency of CD8+ T-cells increased in both mouse types from baseline up to seven days 
post tumour cell grafting and remained steady at ~10% of live cells after this (Figure 
17A). On day 14, seven days post-VLP treatment, lean mice had statistically higher levels 
of CD8+ T-cells (p = 0.0463) however levels were similar at all other time points. 
Frequencies of CD8+ T-cells in both of the mouse types were comparable. 
CD4+ T-cells were initially significantly higher in obese mice (p < 0.0001), however, this 
dropped slightly while in lean mice the population increased at day 7 (Figure 17B). After 
this, frequencies of CD4+ T-cells remained stable and were slightly higher in the obese 
mice than the lean mice at day 7, at around 15% of live cells compared to 10% although 
this was not statistically significant (Figure 17B). 
Lean mice initially had significantly higher amounts of neutrophils at day 0 (p = 0.0050), 
however this decreased by day 7 so that obese mice had a trend of increased frequency 
(Figure 17C). Obese mice had higher levels of inflammatory monocytes than lean mice, 
which was significant at day 14 (p = 0.0098) (Figure 17D).  
Lean mice had significantly higher frequencies of lymphoid-derived DCs initially 
(p = 0.0051 on day 7 and 0.0143 on day 14), however this population decreased on day 
28 to be the same as in the obese mice (Figure 17E). Myeloid-derived DCs had similar 
frequencies in both lean and obese mice and did not fluctuate significantly throughout 
the experiment (Figure 17F).  
Frequencies of B-cells were significantly higher in obese mice at day 0 (p < 0.0001), 
however after seven days since tumour grafting this changed to lean mice having a 
significantly higher amount (p = 0.0293) (Figure 17G). This was because as the tumours 
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grew, levels remained stable in obese mice, while the frequency in lean mice increased 
to statistically significant levels (day 21 p < 0.0001, day 28 p = 0.0002). 
No differences in cell populations between treatment groups in either lean or obese mice 
could be detected. 
  




Figure 17: Analysis of immune cell populations in the blood of tumour-bearing mice 
Lean and obese mice were tail-tipped every 7 days in order to follow the expansion of immune cells during 
immunotherapy treatment. The results represent the mean (± SEM) of five mice per treatment group. 
Statistically significant differences were determined by using a one-way ANOVA. * p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.001, **** p ≤ 0.0001
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4.1 The effect of body composition on 5-year survival of colorectal cancer patients 
4.1.1 Overall patient survival 
To determine whether the data from the murine studies is translatable into clinical 
findings, the effects of obesity on 5-year survival following surgery for the resection of 
colorectal cancer were investigated. Historical patient data was gathered from patients 
enrolled in the Dunedin colorectal cancer cohort. Patients who were diagnosed with stage 
I or II colorectal cancer in 2008-2014 were selected for analysis. From these patients, a 
variety of parameters were able to be considered for survival analysis. This is useful not 
only for investigating the relationship between body composition and overall survival 
(OS), but also to identify any factors that could be confounding the results. 
Measures of obesity used were body mass index (BMI), waist circumference (WC), and 
visceral fat area (VFA). Muscle mass was determined based on the skeletal muscle index 
at the third lumbar vertebra (L3SMI). Ranges for body composition status are displayed 
in Table 2. 
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Table 2: Ranges for determining body composition status 
BMI: Body mass index, WC: waist circumference, VFA: visceral fat area, L3SMI: skeletal muscle index 
at the third lumbar vertebra  
 Underweight Normal Overweight Obese 
BMI (kg/m2) < 18.5 18.5-24.9 25-29.9 > 30 (147) 
WC (cm)  < 93 (females) 
< 100 (males) (148) 
 > 93 (females) 
> 100 (males) 
VFA (cm2)  < 80.1 (females) 
< 163.8 (males) 
(140) 
 > 80.1 (females) 
> 163.8 (males) 





≤ 52.4 (males) 
> 38.5 (females) 
> 52.4 (males) 
(149) 
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The number of patients defined as obese was different depending on the measure. 
Overall, 40.4% of patients with stage I or II colorectal cancer who underwent surgery 
between January 2008 – June 2014 were classified as obese when looking at VFA. When 
looking at BMI, 36.0% of patients were obese, and when considering waist 
circumference, 54.4% of patients were obese. In terms of muscle mass, 52.2% of patients 
were defined as sarcopenic. 
The baseline characteristics for each body composition group are displayed in Table 3. 
Tumour stage, sex, age and smoking status were the only attainable sets of information 
that could be gathered from Health Connect South. 
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Table 3: Baseline characteristics 
Patients were divided into groups based on VFA, L3SMI, BMI, and WC. Proportions of the tumour stage, 
sex, age, and smoking status of patients in each group were calculated. 
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4.1.3 Survival when obesity is defined by VFA and WC 
Overall, 31/136 patients did not reach the 5-year survival point (22.8%). Based on VFA, 
nine patients were non-obese females, six were non-obese males, twelve were obese 
females and four were obese males (22.0%, 15%, 36.4% and 18.2% of the respective 
groups) (Figure 18A). This showed a decrease in OS in obese females, with non-obese 
patients and obese males having similar rates of survival. Based on WC, thirteen patients 
were non-obese females, two were non-obese males, eight were obese females and eight 
were obese males (representing 46%, 8.7%, 22.9% and 20%) (Figure 18B). This 
demonstrated a decrease in OS in non-obese females compared to obese females, but no 
large difference in survival in male patients. None of these groups were statistically 
significantly different. 
  




Figure 18: 5-year survival of stage I and II colorectal cancer patients based on VFA and WC defined 
obesity 
A) Obesity based on VFA (visceral fat area) was defined as > 80.1 cm2 for females and > 163.8 cm2 for 
males. Obese females n=33, obese males n=22, non-obese females n=41, non-obese males n=40.  
B) Based on WC (waist circumference), obesity was defined as > 93 cm for females and > 100 cm for 
males. Obese females n=35, obese males n=39, non-obese females n=39, non-obese males n=23. 
Statistical differences were determined using a Mantel-Cox test. 
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4.1.4 Survival when obesity is defined by BMI, and skeletal muscle index 
BMIs were calculated for 89/136 patients (65.4%), with documented height and weight 
measurements. As there were no sex-specific cut-offs for BMI ranges, and as this would 
reduce group sizes, groups were not split into male and female patients. Of patients who 
had their BMI documented and died after surgery before the 5-year follow up period was 
reached, one was underweight, six were of normal-weight, six were overweight, and five 
were obese (representing 50%, 26.1%, 18.8% and 15.6% of their groups). This showed 
that 5-year survival was similar in overweight and obese patients, and increased 
compared to normal weight patients (Figure 19A) although this was not statistically 
significant. OS was worse in underweight patients, however, this outcome is misleading 
as the cohort was n=2, with one patient surviving past 5 years.  
L3SMIs were determined for 92/136 (67.6%) of patients as height was required for this 
calculation. From this cohort nineteen patients died, of which four were sarcopenic 
females and three were sarcopenic males (representing 21.1% and 11.5%), while nine 
were normopenic females and three were normopenic males (31.0% and 20%). This 
indicated that those who were defined as sarcopenic had a trend of an increased OS 
compared to those with normal muscle mass (Figure 19B). 
  




Figure 19: 5-year survival of stage I and II colorectal cancer patients stratified based on BMI and 
L3SMI 
A) Obesity based on BMI (Body Mass Index), definitions were the following: underweight (< 18.5 kg/m2), 
n=2, normal weight (18.5-24.9 kg/m2), n=23, overweight (25-29.9 kg/m2), n=32, and obese (> 30 kg/m2), 
n=32. 
B) Sarcopenia defined by L3SMI (skeletal muscle index at the third lumbar vertebra) is < 38.5cm2/m2 for 
females and < 52.4 cm2/m2 for males. Sarcopenic females n=19, sarcopenic males n=29, normopenic 
females n=15, normopenic females n=29. 
Statistical differences were determined using a Mantel-Cox test. 
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4.1.5 Survival based on tumour stage and sex of patient 
The four parameters identified as possibly affecting the above results were tumour stage, 
age at the time of surgery, sex, and cigarette smoking status. Out of 136 patients, forty-
six (33.8%) had stage I while ninety (66.2%) patients had stage II colorectal cancer. 11/46 
(23.9%) stage I patients did not reach the 5-year survival point while 20/90 (22.2%) stage 
II patients died, indicating that there is no difference in OS between stage I and II 
colorectal cancer patients (Figure 20A). 
From the cohort, seventy-four (54%) patients were female while sixty-two (45.6%) were 
male. 21/74 (28.4%) of females died and 10/62 (16.1%) of males died, however, this was 
not statistically significant. Overall this shows that males have a trend of increased 5-year 
survival compared with females (Figure 20B).  




Figure 20: 5-year survival of stage I and II colorectal cancer patients based on tumour stage and sex 
Numbers of patients from the cohort in each group:  
A) stage I n=46, stage II n=90. 
B) female n=74, male n=62. 
Statistical differences were determined using a Mantel-Cox test. 
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4.1.6 Survival based on the age and smoking status of patients 
Based on age, 6/136 patients were < 50 years old at the time of surgery, 14/136 were 
between 50-59, 27/136 were between 60-69, 61/136 were between 70-79 and 28/136 
were between 80-89 years old. No patients were aged 90 or above. All patients < 50 and 
between 50-59 years reached the 5-year survival point. 3/27 (11.1%) patients between 
60-69, 16/61 (26.2%) of patients between 70-79, and 12/28 (42.9%) patients between 80-
89 years old died. This showed that patients with colorectal cancer were less likely to 
survive beyond 5 years past surgery over the age of 60 years (Figure 21A). This was 
statistically significant between the ages of 50-59 and 70-79 (p = 0.040), 50-59 and 80-
89 (p = 0.0057), and 60-69 and 80-89 (p = 0.0059). 
Finally, 54/136 patients had never smoked, 15/136 patients smoked at the time of surgery, 
and 38/136 patients were ex-smokers. Information about the smoking status of thirty-two 
patients was not able to be obtained. 7/54 patients (13.0%) who had never smoked, 3/15 
(20%) of current smokers, and 12/38 (31.6%) of ex-smokers died within 5-years post-
surgery. There was a trend that current smokers were at greater risk of dying than people 
who have never smoked. In this cohort, patients who had previously smoked but had quit 
by the time of surgery were at a statistically significantly higher risk of dying than those 
who had never smoked (p = 0.0316) (Figure 21B). 
Overall, this information indicates that differences in body composition groups, such as 
sex, age, and smoking status, but not tumour stage, may be acting as confounding factors 
in this data. 
  




Figure 21: 5-year survival of stage I and II colorectal cancer patients based on age and smoking 
status  
Numbers of patients in the cohort in each group:  
A) < 50 years n=6, 50-59 years n=14, 60-69 years n=27, 70-79 years n=61, 80-89 years n=28. 
B) never smoked n=54, current smoker n=15, ex-smoker n=38. 
Statistical differences were determined using a Mantel-Cox test. * p ≤ 0.05, ** p ≤ 0.01 
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4.2 Differences in markers of inflammation in obesity and sarcopenia 
To examine any differences in immune cell numbers between body composition types, 
patients were stratified based on visceral obesity and muscle mass based on L3SMI. Data 
was obtained from blood tests performed up to 3 months prior to surgery. 
When comparing non-obese and obese patients, there were no statistically significant 
differences however several trends were observed. Eosinophil, monocyte, CEA and 
haemoglobin levels (Figure 22B, D, H, I) were similar in both obese and non-obese 
patients. Basophils, neutrophils and platelet numbers were decreased in obese patients 
(Figure 22A, E, F), while lymphocyte and albumin levels were increased (Figure 22C, 
J). The neutrophil to lymphocyte ratio (NLR), which is a marker of systemic 
inflammation and is the total neutrophil count divided by the total lymphocyte count, was 
decreased in obese patients (Figure 22G) (150). 
Comparing sarcopenic and normopenic patients showed that eosinophil, monocyte, and 
haemoglobin levels were similar (Figure 23B, D, I). Basophils, neutrophils, platelets, 
CEA and albumin levels were raised in sarcopenic patients (Figure 23A, E, F, H, J). 
Lymphocytes were decreased in sarcopenia (Figure 23C). The NLR was raised in 
sarcopenic patients (Figure 23G). 
CEA, which is used clinically as a biomarker for colorectal cancer, is known to be 
increased in patients who smoke cigarettes (151). However, only 11.1% of non-obese 
patients, 9.1% of obese patients, 16.7% of sarcopenic patients and 13.6% of normopenic 
patients smoked at the time of surgery, so this is unlikely to have affected the results 
greatly. 
  




Figure 22: Immune cell populations in the blood of colorectal cancer patients stratified based on 
obesity 
The results represent the mean (± SEM) of 136 patients grouped based on visceral fat area-classified 
obesity. An unpaired student’s t-test was used to assess significance.  
CEA: carcinoembryonic antigen, NLR: Neutrophil/lymphocyte ratio.  




Figure 23: Immune cell populations in the blood of colorectal cancer patients stratified based on 
muscle mass 
The results represent the mean (± SEM) of ninety-two patients grouped based on skeletal muscle index at 
the third lumbar vertebra classified sarcopenia. An unpaired student’s t-test was used to assess significance.
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Over a third of New Zealanders are overweight, obese, or suffer from other metabolic 
disorders, and this rate increases in Māori and Pacific populations (70, 80). Therefore, 
understanding how therapies should be adapted in this setting is an important issue. 
Obesity has been linked to reduced responses to immunotherapies and vaccines, although 
there is some evidence that overweight and obese patients with melanoma respond better 
to immune checkpoint inhibitors (129). Conditions associated with hyperuricemia have 
been found to cause an increase in the risk of developing cancer, and patients who are 
hyperuricemic at the time of cancer diagnosis are more likely to have poorer outcomes 
(84). However, little is known about the effects of uric acid on cancer and cancer therapy. 
Previous experiments in the Young laboratory have demonstrated the efficacy of the 
surv.VLP-SS-MUC1 and surv.VLP vaccines in models of breast and colorectal cancer 
(52, 53, 58, 138, 152). However, these trials only used lean mice. Obesity creates a state 
of chronic inflammation, increases thymic destruction resulting in a reduced number of 
naïve T-cells, and impairs the ability of T-cells to circulate efficiently (110). This 
underlying inflammatory state is important to address when considering the success of 
immunotherapies. Furthermore, clinical trials have seen significant benefits of 
immunotherapies in some patients but not in others, and it would be useful to understand 
possible reasons why there is such a variation in outcome (153). Therefore, the VLP 
treatments previously proven to be efficacious by the Young laboratory were tested in 
mouse models of obesity and hyperuricemia. 
Building on preliminary experiments, this project was centred on a series of tumour trials 
performed in lean, obese, and hyperuricemic mice in order to determine if tumour-
bearing mice responded differently to VLP or VLP in combination with the immune 
checkpoint inhibitor anti-PD-L1. It was hypothesised that combination therapy may be 
beneficial to overcome the effects of these co-morbidities on the immune system. 
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Finally, while murine models are useful, human data is more relevant to medical practice. 
Colorectal cancer patient data was accessed via the Dunedin colorectal cancer cohort. 
This data was used to stratify the cohort based on obesity and muscle mass status and 
assess whether these factors influenced survival up to five years post-surgery. 
Furthermore, cell populations in the blood were analysed for changes potentially 
influenced by these body composition factors. 
5.1 Tumour growth and survival following immunotherapeutic treatment 
Treatment with VLP alone caused a very slight increase in survival in obese and 
hyperuricemic mice compared to lean mice with breast cancer. Conversely, VLP 
combined with anti-PD-L1 treatment resulted in a statistically significant increase in 
survival in lean mice, however, this was not the case in obese and hyperuricemic mice. 
This initial evidence suggests that the underlying metabolic disorders of obesity and 
hyperuricemia cause a diminished response to therapy with checkpoint inhibitors, and so 
treating patients with this kind of therapy who suffer from these conditions may not be 
efficacious. 
In a colorectal cancer setting, VLP treatment resulted in an improvement in survival for 
obese mice, although this was not the case in lean and hyperuricemic mice. The same 
trend was observed in mice treated with VLP + anti-PD-L1. However, these results need 
to be interpreted with some caution as the lean mice grafted with both types of cancer did 
not respond to the treatment as has previously been shown. 
Interestingly, the overall benefit of anti-PD-L1 treatment was decreased in colorectal 
cancer compared to breast cancer. This shows that even at a mouse model level, there is 
a difference between the types of cancers, even though both tumour models expressed 
PD-L1 (136). 
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Other studies have found a significant increase in the efficacy of anti-PD-L1 treatment 
in obese mice and humans (101). This was not the case in the obese mice with breast 
cancer in this study, although it did have increased efficacy in some obese mice in the 
colorectal cancer model. One reason why this benefit was not observed in high amounts 
in the study may have been due to the model of obesity used. In diet-induced obese (DIO) 
mice, leptin levels are increased compared to lean mice, which is positively correlated 
with an increase in PD-1 expression (101). However, leptin receptor-deficient (POUND) 
mice do not have this upregulation (101). While the POUND mice mimic obesity in many 
ways, the changes to the PD-1/PD-L1 pathway may be missing. There are other 
mechanisms which can result in the upregulation of PD-1/PD-L1 expression, however, it 
is likely that this was the reason why an increase in the efficacy of this checkpoint 
inhibitor was not observed in the obese mice. 
An issue encountered during these trials were a significant amount of tumour ulceration. 
This particularly affected the breast cancer trials for all mouse types, and the colorectal 
cancer trial in UrahPlt2/Plt2 mice. Possible reasons for ulcerations include self-induced 
trauma, mechanical trauma (such as tumours rubbing against the bedding), rapid tumour 
growth, or contamination of the tumour (154). Attempts to reduce ulcerations were made 
by ensuring that cages contained only the softest bedding available. The location of the 
breast cancer grafting site was also changed from the second to the fourth MFP to reduce 
rubbing. 
When it became apparent that this issue had affected several different tumour trials 
conducted by different members of the Young laboratory, those involved compared data 
around ulcerations. It was observed that a higher frequency of ulcerations than normal 
started occurring from the end of 2018. Possible reasons were identified as (i) the mice 
may have already been contaminated with a pathogen that was not screened for, (ii) the 
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environment they were housed in, or (iii) the mice may have been inoculated with a 
pathogen at the time of the injection of tumour cells. 
The mice and cell lines were sent to the Cerberus Sciences lab in Australia to be tested 
for possible contamination, however, the results from this are still not available. Recent 
experiments which cultured cells with penicillin and streptomycin saw no ulcerations in 
the mice inoculated with cells grown in the presence of an anti-fungal agent as well, but 
several ulcerations in the mice inoculated with cells not cultured in this. These findings 
further strengthen the hypothesis that a fungal infection was the reason behind the 
ulcerations. As to where this infection was being introduced is currently unknown. As 
the mice that had tumours ulcerate were censored from the data, this reduced the size of 
the groups of mice analysed. In doing so, this affected the power of the statistical analysis. 
The other major issue was the unexpected decrease in efficacy of the VLP to reduce 
tumour growth and increase survival in both breast and colorectal cancer. There are 
several reasons why this may have occurred, considering that an improvement in survival 
had been observed in lean mice using the same VLP treatments previously. The most 
likely reason was that the measured concentration of VLP was incorrect. Before 
treatments were given, the concentration of the VLP was measured using a NanoDrop, 
which measures the amount of protein in a particular sample. Unfortunately, other people 
working in the same laboratory noticed increasingly varied results from this piece of 
equipment, indicating that it may not have been producing reliable results. When 
compared to the Qubit protein assay, the NanoDrop was giving higher readings. This 
may have led to the mice receiving a reduced dose of VLP, hence the treatment not 
working as before. Backing this up is that the only mice who had VLP measured using 
the Qubit assay were the obese mice grafted with colorectal cancer. These mice had the 
greatest improvement in survival when treated by VLP alone. 
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5.2 Frequencies of TILs in breast and colorectal cancer 
To understand why the VLP wasn’t protecting the mice against tumour growth, a small 
number of tumours from lean, obese, and hyperuricemic mice with either breast or 
colorectal cancer were preserved in formalin and stained for lymphocyte infiltration. As 
only two tumours per treatment group were able to be analysed, this meant that statistical 
analysis could not be performed, so all observations made were described as trends. 
However, we were still able to do some basic assessment of T-cell infiltration. 
Previous unpublished work in the Young lab has shown that smaller tumours have a 
greater number of T-cells migrating to the centre of the tumour, but with tumour 
progression T-cells accumulate in the periphery of the tumour. As tumours were only 
removed once they had grown to the maximum size of 150 mm2, fewer T-cells were 
expected to be observed in the centre of the tumours. 
In the breast cancer models, obese and hyperuricemic mice had a diminished frequency 
of TILs compared to lean mice. This pattern was the same in all treatment groups in both 
the centre and peripheral parts of the tumours, except for hyperuricemic mice treated with 
VLP where there was an increase in the amount of T-cells in the periphery. This suggests 
that T-cells in metabolically compromised mice have a reduced ability to invade tumours 
regardless of the treatment, and therefore immunotherapies are less likely to be 
successful. This may have played a role in why these mouse types were not as successful 
as the lean mice in reducing tumour growth when treated with the combination therapy. 
In colorectal cancer tumours, there was no change in the frequency of TILs in obese mice 
treated with PBS or the combination therapy compared to lean mice, with hyperuricemic 
mice having a reduced amount. Interestingly, when treated with VLP the number of TILs 
increased in all areas of the tumour in obese and hyperuricemic mice but decreased 
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slightly in lean mice. This may suggest that the T-cells in the obese and hyperuricemic 
mice had an increased ability to infiltrate the colorectal tumour tissue when stimulated 
compared to lean mice. An increase in TIL frequency is generally thought to be linked to 
greater survival, which was observed in the obese mice (155). 
In the obese mice with colorectal cancer, the VLP group had an increase in median 
survival compared to the PBS group. This can perhaps be explained by the increase in 
TIL frequency in these tumours, whereas survival was not improved by VLP in the lean 
mice, hence a lower frequency of TILs. However, the increase in the frequency of TILs 
in the VLP group in hyperuricemic mice did not result in any improvement in survival, 
suggesting that these lymphocytes may not have been as effective at invoking an effector 
response. A study comparing C57BL/6 mice to UrahPlt2/Plt2 mice found that 
hyperuricemic mice were less capable of causing a reduction in tumour growth when 
given immunotherapeutic treatment against melanoma (131). This difference was 
attributed to a reduction in the proportion of antigen-specific CD8+ T-cells (characterised 
as CD39+, as discussed in section 5.3) (131). However, while hyperuricemic mouse 
tumours underwent immunohistochemical staining, flow cytometric analysis was not 
performed so it cannot be confirmed if this was the case in these mice. This decision was 
made due to the high number of ulcerations in the tumour trials, so in order to reduce the 
numbers of mice used in this project, only lean and obese mice were used for further TIL 
analysis. 
Overall, there was reduced T-cell infiltration in MC-38 tumours compared to 
C57mg.MUC1 tumours. PD-L1 is expressed by MC-38 cells once stimulated by IFNγ, 
while it is present on unstimulated C57mg.MUC1 cells (136). This is likely to have 
caused diminished expression of PD-L1 receptors as CTLs are a source of IFNγ. This 
Discussion  Matthew J. Woodall 
104 
 
may have caused the reduced response to anti-PD-L1 treatment compared to the 
C57mg.MUC1 tumours. 
A higher frequency of CD3+ TILs in the centre of the tumour has been associated with 
an improved response to neoadjuvant chemotherapy in breast cancer (156). The type, 
density, and location of lymphocytes within human colorectal cancers has also been 
shown to be a good predictor of patient survival (157). Therefore, analysing TIL 
distribution and frequency may be important in predicting the outcome of treatment. 
There is not a large number of studies comparing the frequency of TILs in tumours based 
on obesity status, although one study looking at prostatectomy tissue did not find a 
correlation between TIL number and BMI status (158). Evidence from these tumour trials 
has shown a trend towards a difference in TIL frequency between lean, obese, and 
hyperuricemic mice. Interestingly, differences between mouse strains were not consistent 
between breast and colorectal cancer models. This implies that there are more complex 
interactions occurring between the metabolic differences, the types of tumour cells, and 
the TME. 
5.3 Characterisation of TILs in mice grafted with breast or colorectal cancer 
tumours 
An important consideration when looking at TILs is whether they are tumour-specific 
(and so capable of making an effector response against the tumour cells), characterised 
by co-expression of PD-1 and CD39. In the breast cancer model, obesity did not result in 
a difference in the frequency of tumour-specific CD4+ T-cells. CD8+ T-cells, however, 
which are important for tumour cell killing, tended to be more tumour specific in the 
obese mice than the lean mice. Immunotherapeutic treatment did not modulate this 
pattern. 
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It is worth noting that tumours were only stained once they had reached the 150 mm2 
endpoint and hence achieved immune escape. It is possible that the reason there was no 
difference observed in the mice that had immunotherapeutic treatment was that the T-
cells were not phenotyped when they had their greatest effect. Previous unpublished data 
from the Young laboratory stained TILs taken from lean and obese mice as tumours grew 
and showed that there is an increase in tumour-specific T-cells as tumour burden 
increases, however, these cells also become more exhausted. This showed that lean mice 
initially had a higher frequency of antigen-specific CD4+ T-cells. However, by day 21, 
the obese mice had higher numbers. Equal levels of antigen-specific CD8+ T-cells were 
observed at this time point. More research needs to be done into this field to confirm 
these initial findings but this evidence suggests that obese mice may be able to generate 
a stronger antigen-specific T-cell response as tumours burden increases. 
When T-cells are continuously stimulated by antigen, such as in the TME, they are known 
to convert to an exhausted form. Once exhausted, the effector response becomes reduced 
and the numbers of antigen-specific T-cells are depleted (32). This is an important reason 
why cancers are poorly controlled by the immune system. Exhausted T-cells have 
upregulated expression of several inhibitory immune checkpoint receptors such as PD-1 
once initially exhausted, and Tim-3 and LAG-3 when terminally exhausted (32). 
When TILs from breast cancer tissue were stained for these markers, there were 
differences in co-expression of PD-1 and Tim-3, and PD-1 and LAG-3 on T-cells 
between obese and lean mice. LAG-3 expression, which was more common in CD4+ T-
cells than CD8+ T-cells, was raised in obese mice compared to lean mice. Conversely, 
PD-1+ Tim-3+ T-cells, which were at similar levels for both T-cell subtypes, were reduced 
in obese mice. As both receptors are upregulated in terminally exhausted T-cells, it was 
expected that if obesity caused an increase in T-cell exhaustion there would have been 
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an increase in the expression of both markers in these mice. One study found that CD8+ 
TILs in DIO mice expressed higher levels of PD-1, Tim-3 and LAG-3 compared to lean 
mice (101). It was unclear as to why Tim-3 was downregulated in the TILs of obese mice 
in this study. 
T-cells were also isolated from the spleens of mice with breast cancer in each treatment 
group. As the cells were located within tumour-free tissue, they can be used to compare 
the functionality of T-cells in the periphery versus those localised in the tumour (159). 
Expression of all markers of exhaustion were downregulated in splenocytes compared to 
TILs, so the high rate of exhaustion in the TILs was most likely due to the tumour tissue 
as opposed to being a baseline characteristic of the T-cells. There were trends of an 
increase in expression of all markers of exhaustion in the obese mice compared to lean 
mice. This could mean that in this study, obesity resulted in a higher level of T-cell 
exhaustion. This would mean that the T-cells were less capable of making a meaningful 
response against the tumour cells in the first place. 
In the colorectal cancer model, both lean and obese mice had similar frequencies of 
tumour-specific T-cells, which increased in both treatment groups. In conjunction with 
the information about the frequency of TILs inside the tumour tissue, it shows that while 
there was no difference in total T-cell numbers, the percentage of cells which were 
tumour specific increased with treatment. 
The frequency of terminally exhausted CD8+ T-cells in mice grafted with colorectal 
cancer showed a trend of generally increasing in the VLP and VLP + anti-PD-L1 
treatment groups compared to the PBS group. This observation was similar in both lean 
and obese mice. 
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It is interesting that obesity did not cause a difference in either T-cell infiltration 
frequency or the rate of T-cell exhaustion in mice grafted with colorectal cancer, while 
in the breast cancer models obese mice had both a reduction in T-cell infiltration and a 
general trend of increased exhaustion. MC-38 tumours also had a much lower rate of T-
cell invasion than C57mg.MUC1 tumours. As the TME varies between tumour types, 
this is plausible. The importance of this is that when modulating VLP-based 
immunotherapies for different types of cancers, it may not be just a matter of changing 
epitopes. If certain environments are more difficult or hostile to infiltrate, this will also 
have to be mediated. 
As detailed earlier, there was a reduced response to the VLP treatment in both cancer 
types compared to what had been shown in previous studies. Therefore, T-cell exhaustion 
may be different in mice with tumours that had successfully reduced growth as a result 
of the treatment. Once the problem with the VLP has been resolved, it would be beneficial 
to repeat this staining, because there may be other factors at play causing the T-cell 
exhaustion. 
As will be discussed in section 5.8, analysis of TILs in tumours of non-obese and obese 
humans could be investigated in the future. However, from this data, obese patients may 
have increased benefit from anti-LAG-3 treatment against breast cancer compared to lean 
patients, while lean patients may benefit from treatment with anti-Tim-3. Both lean and 
obese patients with colorectal cancer may benefit equally from these treatments. Anti-
LAG-3 therapies are currently in clinical trials, while anti-Tim-3 is a less desirable target 
due to being expressed on a variety of immune cells (160). 
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5.4 Changes to immune populations in the blood following MC-38 tumour 
challenge 
As this project was being undertaken, it was decided that it would be beneficial to see if 
there were any changes to the frequencies of different types of immune cells in the blood. 
Along with T-cells and DCs, other immune cells measured were B-cells (which produce 
antibody in response to a foreign antigen), neutrophils (one of the most common white 
blood cells to respond to an injury or infection), and inflammatory monocytes (contribute 
to inflammation by secreting cytokines into the blood, and can differentiate into 
macrophages in tissue) (161). This was only performed for the colorectal cancer models, 
but differences observed in the breast cancer model would be useful to elucidate at a later 
date. 
Following tumour-grafting, neutrophils and inflammatory monocyte counts were raised 
in obese mice, which also had reduced frequencies of lymphoid-derived DCs and B-cells 
compared to lean mice. Neutrophils and inflammatory monocytes have previously been 
shown to be increased in obesity, and an increase in these innate immune cells correspond 
to the chronic level of inflammation seen in this disease state (162). DCs are crucial for 
the presentation of antigens to cells of the adaptive immune system. If obesity causes a 
reduction in the levels of these cells, it may result in a reduced ability of the immune 
system to respond to immunotherapies. The secretion of antibody by B-cells, while not 
studied in this context, is important for the function of most vaccines and so this data also 
backs up previous research surrounding a reduced long-term efficacy of vaccines in obese 
patients (127). 
Obese mice had higher levels of CD4+ T-cells before therapy was initiated compared to 
lean mice, although the level of CD8+ T-cells was similar in both mouse types. This is 
consistent with clinical findings, where obesity has been linked to a higher total 
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lymphocyte count (163, 164). However, after tumour-grafting the frequency of CD4+ T-
cells in lean mice increases to be similar to that of the obese mice. Similarly, CD8+ T-
cells were higher in lean mice compared to obese mice a week. This could mean that the 
underlying inflammation brought about by obesity meant that these mice were unable to 
create as strong a T-cell response against the tumour cells. No differences in the 
frequency of any of the immune cells measured were found between the treatment 
groups. 
Clinical trials have found that an increased lymphocyte count following 
immunotherapeutic treatment is positively correlated with prognosis (165). There were 
no difference in circulating T-cell frequency between treatment groups in either mouse 
type, which could help to explain the low overall response rate in the mice. 
In July 2019 a paper was published which outlines a comprehensive method to monitor 
a variety of immune populations using flow cytometry (166). It is yet to be seen if this 
will be taken on board in clinical trials, and whether information from this correlates with 
the data found here. 
5.5 The role of body composition in the survival of patients with colorectal cancer 
There have been very few studies performed which look at how obesity affects the 
survival of cancer patients, and those that do use BMI as an index of obesity. There are 
currently several different ways that obesity can be measured, with growing consensus 
that measuring visceral adipose tissue may look more specifically at the pathological 
effects of fat (132). 
In this project, data from stage I and II colorectal cancer patients were analysed for the 
impact of obesity on cancer outcomes. These patients were chosen because they were 
less likely to be cachexic than those with more advanced disease. Cachexia causes severe 
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weight loss and muscle wasting, and strongly influences the body composition status of 
patients, hence acting as a confounding factor (167). Limiting the cohort to only stage I 
and II patients aimed to reduce the effect of this. Furthermore, because it was unknown 
from the outset of the project how many patients would have obtainable data, only stage 
I and II patients were used in order to make data extraction feasible in the time frame 
allowed for this project. 
BMI is a frequently used measure of obesity in the clinic. Similar to observations in other 
studies, overweight and obese patients classified by BMI had a trend of slightly higher 
rates of survival than normal-weight patients (105, 106). WC is also commonly used, 
however, interestingly the effect of obesity differed by sex. When measuring WC, female 
obese patients had a higher rate of survival than their non-obese counterparts. In male 
patients, obesity had the opposite effect. Female patients had lower survival rates than 
males. 
As mentioned, visceral adiposity has a greater pathology associated with it and may prove 
to be more useful when looking at the effects of obesity on disease outcome. Compared 
to BMI and WC, it takes longer to obtain this measurement as a CT scan is required. 
However, if a scan is already available then it only takes a few minutes to measure that 
fat mass and interpret the results. Furthermore, once trained correctly a radiologist would 
not be required to perform this task. 
Obesity measured in this way gave different outcomes than when measured by BMI or 
WC. Females (both non-obese and obese) had a trend towards worse survival than males, 
with obese females having lower survival rates than non-obese females. Obese males, 
non-obese males, and non-obese females had similar survival rates. This is interesting 
for several reasons. Firstly, when taking the measurements, it was noticed that many of 
the patients had significant fat mass in the subcutaneous fat layer however they had 
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minimal fat within the abdominal wall. This resulted in these patients being defined as 
obese by waist circumference (and most likely by BMI) but non-obese by VFA. This 
shows that there is a group of patients who would normally be defined as obese but have 
a low amount of fat in the abdominal cavity, which is more pathological. Secondly, 
measuring obesity by VFA accounts for differences in the distribution of fat between 
men and women. Men store up to 30% of their total body fat in the abdominal 
compartment regardless of obesity status whereas women collect adipose tissue 
peripherally and only attain significant visceral fat once some level of obesity has been 
reached (140). By measuring VFA using sex-specific thresholds, this difference can be 
accounted for. 
The differences observed in overall survival between men and women is likely due to the 
differences in fat deposition. Compared to men, women have a higher body fat 
percentage however more of this is in the subcutaneous and gluteo-femoral regions than 
the intra-abdominal region (168). This distribution has been linked to a decreased risk of 
diabetes, cardiovascular disease, and overall morbidity and mortality. Furthermore, 
women who have higher rates of fat deposition in the abdomen suffer from the same 
metabolic issues as men (168). Studies have also found that increase visceral adipose 
tissue is an independent risk factor for colorectal adenoma, whereas an increase in 
subcutaneous adipose tissue can be beneficial (169, 170). This may explain why an 
increase in survival in obese women was observed when obesity was determined by waist 
circumference. This will largely be considering subcutaneous tissue, as opposed to VFA, 
which only focuses on the disadvantageous visceral adipose tissue. Men have a higher 
amount of visceral adipose tissue to start with, so more of the waist circumference 
measurement will be related to the amount of visceral fat the male patients have. This 
may explain why obese males have worse survival rates when classified by waist 
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circumference. It is currently unclear why there was no difference in males based on 
VFA. 
The other aspect of body composition is muscle mass, which is decreased in the elderly 
and associated with several chronic conditions (77). When split into groups based on 
sarcopenia, surprisingly the normopenic patients had a trend of a lower survival rate than 
the sarcopenic patients. This was the same for both females and males, with both groups 
of females having reduced survival rates when compared to the male groups. This data 
conflicts with currently available evidence, which has shown that sarcopenia is correlated 
with increased mortality in a variety of cancer types, including head and neck cancer, 
non-small cell lung cancer, breast cancer, and colorectal cancer (108, 171-173). 
One reason why this outcome may be different is that only patients with stage I and II 
colorectal cancer were investigated, so the majority of these patients would not have had 
follow-up chemotherapy or radiotherapy after their cancer resection surgery. Most 
studies performed in this area have expanded to all stages, with muscle mass affecting 
the outcome of additional treatments. The measurements for obesity were defined in 
European cohorts. 30% of people living in New Zealand identify as being an ethnicity 
other than of European origin, with the largest group being Māori (174). It is known that 
fat distribution differs by ethnicity, however, this was not accounted for in this 
study (175). 
There are also limitations with using a skeletal muscle index for classifying sarcopenia. 
Firstly, the diagnosis of sarcopenia is usually multi-faceted, involving both assessment 
of muscle mass (e.g. CT scans) as well as physical performance measures (176). As the 
latter was not available, CT scans alone were used to classify the population. Secondly, 
normalising the muscle cross-sectional area to create a skeletal muscle index involved 
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the patient’s height. Only 67.6% of patients had this information recorded, which limited 
the sample size. 
Patient sex, age and smoking status at the time of cancer resection surgery were identified 
as influencing 5-year survival in this cohort. When looking at the baseline characteristics 
of the different groups, age was fairly evenly distributed. However, because there were 
statistically significant differences between the groups it would be important to account 
for this. There were differences in the smoking status and sex of patients in different 
groups. These were therefore likely to be acting as confounders and would need to be 
accounted for in further analysis. 
5.6 Changes in immune cells frequencies based on body composition 
Given the difference in outcomes observed for obese patients when using VFA as a 
measure, markers of inflammation in the blood were analysed to see if any changes here 
could explain this finding. Using results from the full blood count and other blood tests 
that patients had before surgery, trends were able to be observed between patients based 
on obesity (defined by VFA) and sarcopenia (defined by skeletal muscle index). 
Obesity causes a state of chronic inflammation, with several studies finding an increase 
in the total lymphocyte, CD4+ and CD8+ T-cell count (163, 164). Our data confirms this 
finding, with the lymphocyte count being raised in obese patients. Information on specific 
types of lymphocytes was not able to be gathered, although this would be interesting to 
investigate. Other cell populations such as neutrophils and platelets have also been 
reported to be elevated in obesity, such as were reported in section 5.4 (162). 
Interestingly, data from this project does not corroborate with this, having found that cell 
counts for neutrophils and platelets were decreased in obesity. NLR is not thought to be 
correlated with increased BMI, however, in the patients analysed here, this was decreased 
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(177). The reduction in NLR indicates an increase in lymphocyte count but a decrease in 
neutrophil count. 
Albumin is the most abundant protein in the plasma, making up approximately 52% of 
the total plasma protein content. Studies have found that albumin levels are reduced in 
obese states, with a negative correlation between BMI and albumin levels (178). This is 
likely due to albumin being a negative acute-phase protein, which decreases in response 
to inflammatory cytokines (179). As obesity stimulates an increase in pro-inflammatory 
cytokines such as TNFα, albumin levels would decrease (113). However, the results from 
this project show an increase in albumin levels in the obese group. Colorectal cancer 
itself may have had an impact on the findings. While patients with colorectal cancer in 
the ascending colon or rectum have not been correlated with a variation in albumin levels, 
those with cancer in the descending colon have been shown to have increased levels of 
albumin (180). Information on the location of tumours was not able to be gathered for 
this study. 
Research into levels of immune cells as well as other markers of inflammation in 
sarcopenia is considerably lacking. One study found that sarcopenic patients have lower 
levels of haemoglobin and albumin (181). However, in this project, there was no change 
in haemoglobin levels and some increase in albumin levels. Lymphocyte counts have 
been found to be decreased and NLR increased in sarcopenic patients with small cell lung 
cancer (182, 183). Results from this project are in agreement with this. As lymphocytes 
make up the majority of the adaptive wing of the immune system, a decrease in these 
cells would result in a decreased ability to protect the body against foreign invaders or 
tumours, and may contribute to why sarcopenic patients have reduced cancer survival 
rates in most studies. 




Several issues occurred in this project, which are likely to have affected our results. 
Problems around a high frequency of ulcerations, and the VLP not working as observed 
in other trials previously have been explained in section 5.1. 
Another limitation was the strain of mice used. The model used for obesity was the 
POUND mice, which have a deletion mutation in exon two of the leptin receptor gene on 
chromosome four, resulting in it lacking the leptin receptor (134). Leptin causes satiety, 
so this mutation renders mice unable to control the urge to eat. They quickly display 
features of metabolic syndrome from 8 weeks of age. This makes it an easy model to 
study obesity as opposed to DIO mice. However, as discussed earlier there was no 
consistently significant increase in efficacy of anti-PD-L1 treatment in the obese mice 
that other studies have shown and this may be due to the mutation itself. DIO mice may, 
therefore, be a better model to use in future work. 
5.8 Future directions 
Due to the change in the efficacy of the VLP observed in this project, many of the tumour 
trials will have to be repeated. Before this is done, the underlying issues of protein 
concentration measurements, tumour ulceration, and possible contamination of either the 
tumour cell lines or mice, need to be resolved. 
A different assay (Qubit) was used for the final VLP injections to double-check 
concentrations and will continue to be used in future tumour trials. Changes in technique 
such as loading syringes with tumour cells in a sterile hood before going to the animal 
facility instead of loading there will reduce the chance of contamination. Tumours that 
ulcerated have also been tested for bacteria by swabbing a small amount and allowing to 
Discussion  Matthew J. Woodall 
116 
 
grow on a Luria-Bertani agar plate. An overgrowth of Staphlococcus xylosus was found 
in one of the ulcerated tumours. 
Due to the high amount of ulcerations in these trials, tumours from the UrahPlt2/Plt2 mice 
were unable to be analysed via flow cytometry. Running the exhaustion panel on these 
tumours would allow for a more complete story and would complement the data on TIL 
frequency. 
The tumour trials were designed based on the assumption that the VLP was an efficacious 
treatment and that combination therapy with anti-PD-L1 would increase the benefit. 
However, due to the VLP not working, and with the VLP + anti-PD-L1 groups showing 
some reduced growth and increased survival, it may be useful to have a group of mice 
treated with just anti-PD-L1 in order to see the effect of this drug alone. 
Finally, only stage I and II colorectal cancer patients have been investigated in the 
Dunedin cohort. This project will be continued next year, expanding to stage III and IV 
patients. These patients are more likely to have had chemotherapy and will more closely 
resemble the mouse work undertaken. Once the data from this has been analysed, it will 
provide a more complete picture of the differences already observed between groups 
based on muscle and fat mass. Stage III and IV patients are expected to have a reduced 
rate of survival, and studies tend to show that obesity has a greater effect in the more 
advanced stages of cancer (105). 
Possible confounders, such as sex, age and smoking status, have been outlined. However, 
the results have not been adjusted for them yet as this was outside the scope of this 
project. This will be performed by a biostatistician before publishing. Ethnicity should 
also be accounted for when moving forward with this project. 
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As these patients are enrolled in the Dunedin colorectal cancer cohort, samples of the 
tumours are preserved and can be accessed. In this project, immune cell populations in 
the blood of these patients have been looked at. It would be interesting to look at the 
types of immune cells within the tumours or see the level of T-cell exhaustion. This could 
be done via immunohistochemical staining and would help further link this study to the 
murine component of the research. 
5.9 Conclusion 
Cancer is a disease which causes significant global morbidity and mortality. Especially 
in more advanced stages, it is complex to treat due to its ability to metastasise and adapt 
to current therapies. Immunotherapies are a promising new technology which are likely 
to become the future of cancer treatment. However, many of these treatments are still in 
novel stages and there are major discrepancies around who will benefit as many patients 
do not respond favourably. Metabolic syndrome, primarily obesity, has been identified 
as a possible influencer of immunotherapeutic treatment outcome due to its effect on the 
immune system. Among other things, the state of chronic inflammation induced by 
obesity both works to encourage tumour growth and may make it harder for treatments 
to stimulate the immune system, impeding success. 
Previous work on this project found that obese mice may have a more 
immunosuppressive environment, while hyperuricemic mice may have impaired 
activation of certain immune cells. Due to the issues highlighted previously, it is difficult 
to make conclusions from this data. However, breast cancer tumour-bearing lean mice 
responded more favourably to anti-PD-L1 compared to obese and hyperuricemic mice. 
A higher frequency of TILs in the tumours of lean mice compared to obese and 
hyperuricemic mice may be responsible for this, although, in the colorectal cancer 
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tumours, lean and obese mice had similar levels of TILs while hyperuricemic mice were 
reduced. 
It was found that classifying obesity by visceral fat gives a different pattern of 5-year 
survival in stage I and II colorectal cancer patients compared to classifying it by waist 
circumference or BMI. This is important as it means that current clinical methods for 
classifying obesity may not be accurately reflecting the effect of specific types of fat on 
health outcomes. More work needs to be done to expand this study to stage III and IV 
patients to complete the picture. 
Overall, metabolic syndrome has a role to play in the efficacy of cancer treatment, and 
this may be cancer type and sex specific. Rates of obesity are increasing globally, which 
comes with a raft of different health problems. It is therefore important to tailor current 
and future cancer treatments, in order to obtain the best health outcomes for all 
populations of patients.
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Supplementary Figure 1: Markers of T-cell exhaustion in spleens of C57mg.MUC1 mice 
The results represent the mean (± SEM) of five mice per treatment group. Statistical differences were 
determined by using a one-way ANOVA. 





20 g dextrose 
8 g sodium citrate 
0.55 g citric acid 
4.2 g NaCl 
1 L Milli-Q deionised water 
Complete Phosphate-Buffered Solution (cPBS) 
5.2 g NaH2PO4 
23.66 g Na2HPO4 
17.54 g NaCl 
2 L distilled water 
C57mg.MUC1 Cell Media 
45 mL Dulbecco’s Modified Eagle Medium (Gibco) 
5 mL (10%) Foetal Calf Serum (FCS) (Moregate Biotech) 
150 µg/mL geneticin (G418) (Gibco) 
Dulbecco’s Phosphate-Buffered Solution (DPBS) 
10 g Dulbecco’s PBS powder (Gibco) 
1 L Milli-Q deionised water 
Sterile filtered 
Ethylenediaminetetraacetic acid (EDTA) solution 
1 mM EDTA in DPBS 
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Fluorescence-Activated Cell Sorting (FACS) buffer 
1 g (1%) bovine serum albumin 
0.1 g (0.1%) NaN3 
2 mM EDTA 
1 L 10x PBS 
Sterile filtered, dilute 1:9 in Milli-Q deionised water 
MC-38 Cell Media 
45 mL Dulbecco’s Modified Eagle Medium 
5 mL (10%) Foetal Calf Serum (FCS) 
8% Paraformaldehyde (PFA) Fixation Buffer 
8 g paraformaldehyde 
100 mL FACS buffer 
Red Blood Cell Lysis Buffer 
4.15 g NH4Cl 
0.5 g KHCO3 
0.0186 g EDTA 
500 mL Milli-Q deionised water 
Sterile filtered 
Trypan blue solution 
0.25 g Trypan blue powder (Sigma-Aldrich) 
100 mL 1 x PBS solution 
Sterile filtered 
